<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Neuropsychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Neuropsychopharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">2689</journal-id><journal-id journal-id-type="pmc-domain">ijneuro</journal-id><journal-id journal-id-type="publisher-id">ijnp</journal-id><journal-title-group><journal-title>International Journal of Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1461-1457</issn><issn pub-type="epub">1469-5111</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11792077</article-id><article-id pub-id-type="pmcid-ver">PMC11792077.1</article-id><article-id pub-id-type="pmcaid">11792077</article-id><article-id pub-id-type="pmcaiid">11792077</article-id><article-id pub-id-type="pmid">39831679</article-id><article-id pub-id-type="doi">10.1093/ijnp/pyaf005</article-id><article-id pub-id-type="publisher-id">pyaf005</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00415</subject><subject>AcademicSubjects/SCI01870</subject></subj-group></article-categories><title-group><article-title>The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3928-3194</contrib-id><name name-style="western"><surname>Tuncturk</surname><given-names initials="M">Mustafa</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/writing-original-draft" degree-contribution="equal">Writing - original draft</role><aff>
<institution>Department of Psychiatry and Psychology, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kushwaha</surname><given-names initials="S">Shikha</given-names></name><degrees>PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role><aff>
<institution>Department of Psychiatry and Psychology, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heider</surname><given-names initials="RM">Robin M</given-names><suffix>BS</suffix></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role><aff>
<institution>Department of Psychiatry and Psychology, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oesterle</surname><given-names initials="T">Tyler</given-names></name><degrees>MD, MPH</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role><aff>
<institution>Department of Psychiatry and Psychology, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weinshilboum</surname><given-names initials="R">Richard</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role><aff>
<institution>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3757-3924</contrib-id><name name-style="western"><surname>Ho</surname><given-names initials="MF">Ming-Fen</given-names></name><degrees>PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="equal">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/writing-original-draft" degree-contribution="equal">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role><xref rid="c1" ref-type="corresp"/><aff>
<institution>Department of Psychiatry and Psychology, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country country="US">United States</country></aff></contrib></contrib-group><author-notes><corresp id="c1">Corresponding author: Ming-Fen Ho, PhD, Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States (<email>ho.mingfen@mayo.edu</email>)</corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-01-20"><day>20</day><month>1</month><year>2025</year></pub-date><volume>28</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">481232</issue-id><elocation-id>pyaf005</elocation-id><history><date date-type="received"><day>04</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2025</year></date><date date-type="editorial-decision"><day>10</day><month>1</month><year>2025</year></date><date date-type="corrected-typeset"><day>04</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-11 17:25:20.443"><day>11</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of CINP.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pyaf005.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pyaf005.pdf"/><abstract><title>Abstract</title><p>Opioid use disorder (OUD) affects over 40 million people worldwide, creating significant social and economic burdens. Medication for opioid use disorder (MOUD) is often considered the primary treatment approach for OUD. MOUD, including methadone, buprenorphine, and naltrexone, is effective for some, but its benefits may be limited by poor adherence to treatment recommendations. Immunopharmacotherapy offers an innovative approach by using vaccines to generate antibodies that neutralize opioids, blocking them from crossing the blood-brain barrier and reducing their psychoactive effects. To date, only 3 clinical trials for opioid vaccines have been published. While these studies demonstrated the potential of opioid vaccines for relapse prevention, there is currently no standardized protocol for evaluating their effectiveness. We have reviewed recent preclinical studies that demonstrated the efficacy of vaccines targeting opioids, including heroin, morphine, oxycodone, hydrocodone, and fentanyl. These studies showed that vaccines against opioids reduced drug reinforcement, decreased opioid-induced antinociception, and increased survival rates against lethal opioid doses. These studies also demonstrated the importance of vaccine formulation and the use of adjuvants in enhancing antibody production and specificity. Finally, we highlighted the strengths and concerns associated with the opioid vaccine treatment, including ethical considerations.</p></abstract><kwd-group><kwd>opioid use disorder</kwd><kwd>vaccine therapy</kwd><kwd>immunopharmacotherapy</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="DOI">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>R01 DA57928</award-id><award-id>K01 AA28050</award-id><award-id>R01 AA27486</award-id><award-id>R18 HS29774</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>the Brain &amp; Behavior Research Foundation</institution></institution-wrap></funding-source><award-id>31329</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Mayo Clinic Research Pipeline K2R Program</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Terrance and Bette Noble Foundation</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Mayo Clinic Center for Individualized Medicine</institution><institution-id institution-id-type="DOI">10.13039/100014535</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>IMMUNOPHARMACOTHERAPY FOR OPIOID USE DISORDER</title><p>Opioid use disorder (OUD) impacts over 40 million individuals globally and gives rise to a high economic burden on society.<sup><xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0002" ref-type="bibr">2</xref></sup> Medication for opioid use disorder (MOUD) is often considered the primary treatment approach for OUD.<sup><xref rid="CIT0003" ref-type="bibr">3</xref>,<xref rid="CIT0004" ref-type="bibr">4</xref></sup> The US Food and Drug Administration (FDA) has approved 3 medications for the treatment of OUD, including methadone, buprenorphine, and naltrexone.<sup><xref rid="CIT0005" ref-type="bibr">5</xref>,<xref rid="CIT0006" ref-type="bibr">6</xref></sup> In addition, naloxone, a &#956;-opioid receptor antagonist, can be used to reverse overdose effects.<sup><xref rid="CIT0007" ref-type="bibr">7</xref>,<xref rid="CIT0008" ref-type="bibr">8</xref></sup> Moreover, nalmefene, an opioid receptor antagonist, was recently approved by the FDA for the treatment of opioid overdose.<sup><xref rid="CIT0009" ref-type="bibr">9</xref></sup> Current treatments for OUD are effective. However, many patients with OUD return to opioid use at some point within their lifetime. Staying in treatment significantly reduces the risks of overdose or opioid-involved overdose death. Therefore, an opioid vaccine could serve as a valuable complement to existing treatments for OUD, enhancing long-term recovery efforts. Despite receiving MOUD, the relapse rate during drug therapy can reach approximately 90% within a 1-year period.<sup><xref rid="CIT0010" ref-type="bibr">10-12</xref></sup> Immunopharmacotherapies emerged as a prospective treatment strategy for OUD as early as the 1970s.<sup><xref rid="CIT0013" ref-type="bibr">13</xref>,<xref rid="CIT0014" ref-type="bibr">14</xref></sup> In 1974, Bonese et al. demonstrated the potential of active immunization by using a morphine-based hapten conjugated to bovine serum albumin (BSA), resulting in antibodies that reduced intravenous heroin self-administration in non-human primates.<sup><xref rid="CIT0015" ref-type="bibr">15</xref></sup> Although the concept of anti-opioid vaccines was introduced in the 1970s, interest in opioid vaccines increased significantly during the 1990s. This renewed interest was driven by the initiation of clinical trials for vaccines targeting cocaine and nicotine.<sup><xref rid="CIT0016" ref-type="bibr">16-18</xref></sup></p><p>Immunopharmacotherapies for OUD primarily involve monoclonal antibodies and opioid vaccines.<sup><xref rid="CIT0019" ref-type="bibr">19</xref>,<xref rid="CIT0020" ref-type="bibr">20</xref></sup> Monoclonal antibodies provide rapid, reversible protection by directly neutralizing opioids in the bloodstream, making them suitable for acute overdose scenarios or when opioid pain relief is needed.<sup><xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0022" ref-type="bibr">22</xref></sup> A recent preclinical study demonstrated that monoclonal antibodies against the fentanyl class of drugs including fentanyl and carfentanil reduced the effects of both drugs in a dose-responsive manner in mouse antinociception models.<sup><xref rid="CIT0023" ref-type="bibr">23</xref></sup> Another preclinical study reported that monoclonal antibodies reversed fentanyl-induced antinociception, respiratory depression, and bradycardia, and that rats retained protection against additional challenges for at least 1 week.<sup><xref rid="CIT0024" ref-type="bibr">24</xref></sup> Nevertheless, monoclonal antibodies require frequent dosing and are costly, limiting their accessibility.<sup><xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0023" ref-type="bibr">23</xref></sup> Vaccines, in contrast, induce a long-lasting immune response that blocks opioids from reaching the brain, offering a more cost-effective and sustained prevention option. However, their prolonged action may pose challenges if patients need opioid-based pain management. By treating with opioid antigens, the vaccines prompt the production of antibodies that specifically bind to opioids, preventing their passage across the blood-brain barrier and subsequent psychoactive effects.<sup><xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0017" ref-type="bibr">17</xref></sup> Specifically, opioids are rapidly metabolized into multiple active compounds, which can be specifically targeted by vaccines to block their metabolites from crossing the blood-brain barrier. By preventing the formation of active metabolites, these vaccines may also reduce craving and compulsive use.<sup><xref rid="CIT0016" ref-type="bibr">16</xref>,<xref rid="CIT0025" ref-type="bibr">25</xref></sup> Most studies of substance use disorder vaccines involve psychoactive substances such as nicotine, cocaine, oxycodone, heroin, or fentanyl&#8212;compounds that have low intrinsic immunogenicity. Thus, they are often conjugated to immunogenic proteins, and the opioids themselves function as haptens to stimulate antibody production.<sup><xref rid="CIT0026" ref-type="bibr">26-28</xref></sup> Commonly used protein conjugates include adenovirus capsid proteins, keyhole limpet hemocyanin, and tetanus toxoid.<sup><xref rid="CIT0029" ref-type="bibr">29</xref>,<xref rid="CIT0030" ref-type="bibr">30</xref></sup> Preclinical animal studies play a pivotal role in demonstrating the efficacy and safety profiles of vaccines designed for the treatment of OUD.<sup><xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0031" ref-type="bibr">31</xref></sup> Those studies are typically conducted in rodent models and involve administering opioid vaccines to evaluate their capacity to elicit a robust immune response and mitigate the behavioral and neurobiological effects associated with opioid exposure. The outcomes of these preclinical investigations inform the rational design and optimization of vaccine formulation, dosage regimens, and adjuvant strategies, thereby guiding the selection of potential candidates for clinical trials.<sup><xref rid="CIT0017" ref-type="bibr">17</xref>,<xref rid="CIT0018" ref-type="bibr">18</xref>,<xref rid="CIT0031" ref-type="bibr">31</xref></sup></p></sec><sec id="s2"><title>PRECLINICAL AND CLINICAL VACCINE STUDIES: TARGETING HEROIN AND MORPHINE</title><p>Heroin is a schedule 1 substance under the Controlled Substances Act. Notably, approximately 727&#8197;000 individuals died from opioid overdoses between 1999 and 2022, with the rise in deaths occurring in 3 distinct waves. The first wave began in the 1990s with the increased prescribing of opioids, including natural and semi-synthetic opioids and methadone, although these deaths have decreased in recent years. The second wave began in 2010, marked by a sharp rise in overdose deaths related to heroin. However, recent years have seen a decline in heroin-related overdose fatalities. The third wave began in 2013, with a significant increase in overdose deaths involving synthetic opioids, especially those linked to illegally manufactured fentanyl and its analogs.<sup><xref rid="CIT0032" ref-type="bibr">32-34</xref></sup> The development of a vaccine against heroin is challenging because of the complexity of heroin metabolism and the rapid generation of active metabolites (ie, 6-acetylmorphine (6-AM), and morphine).<sup><xref rid="CIT0035" ref-type="bibr">35</xref>,<xref rid="CIT0036" ref-type="bibr">36</xref></sup> Heroin is rapidly converted to 6-AM and subsequently transformed into morphine, and this is an imperative for vaccine design.<sup><xref rid="CIT0035" ref-type="bibr">35-37</xref></sup> Successful vaccine development hinges on the meticulous design of haptens, particularly targeting 6-AM, the principal psychoactive compound.<sup><xref rid="CIT0017" ref-type="bibr">17</xref></sup> The pioneering studies in the 1970s led by Wainer and Berkowitz laid the groundwork for morphine vaccine development,<sup><xref rid="CIT0038" ref-type="bibr">38-40</xref></sup> providing foundational insight into the production of morphine-specific antibodies. Immunization produces antibodies,<sup><xref rid="CIT0038" ref-type="bibr">38</xref>,<xref rid="CIT0040" ref-type="bibr">40</xref>,<xref rid="CIT0041" ref-type="bibr">41</xref></sup> which in turn alter neurobehavioral phenotypes induced by heroin, such as reduced antinociceptive effects<sup><xref rid="CIT0042" ref-type="bibr">42</xref></sup> and suppression of hypermotor activity.<sup><xref rid="CIT0041" ref-type="bibr">41</xref></sup> Furthermore, immunization against morphine with high-avidity antibodies reduces the concentration of free, metabolically active compounds in the serum, as well as their pharmacological effects.<sup><xref rid="CIT0039" ref-type="bibr">39</xref>,<xref rid="CIT0040" ref-type="bibr">40</xref></sup> Notably, immunization of chicken eggs with a morphine vaccine showed no significant adverse effects on growth or development,<sup><xref rid="CIT0043" ref-type="bibr">43</xref></sup> demonstrating the potential safety of this vaccine. These findings from preclinical studies underscore the complex interplay between immunization, physiological responses, and pharmacological outcomes in modulating morphine effects (<xref rid="sup1" ref-type="supplementary-material">Table S1</xref>).</p><p>Effective vaccination impedes the distribution of heroin and its metabolites, particularly 6-AM, to the brain.<sup><xref rid="CIT0037" ref-type="bibr">37</xref>,<xref rid="CIT0044" ref-type="bibr">44-46</xref></sup> This inhibition plays a crucial role in mitigating the reinforcing effects of heroin and its compulsive self-administration, characterized by a persistent and uncontrollable pattern of use.<sup><xref rid="CIT0037" ref-type="bibr">37</xref>,<xref rid="CIT0045" ref-type="bibr">45</xref>,<xref rid="CIT0047" ref-type="bibr">47</xref></sup> These vaccines demonstrate effectiveness in preclinical models by reducing (1) heroin-induced antinociception,<sup><xref rid="CIT0044" ref-type="bibr">44</xref>,<xref rid="CIT0048" ref-type="bibr">48</xref>,<xref rid="CIT0049" ref-type="bibr">49</xref></sup> (2) heroin-induced locomotor activity,<sup><xref rid="CIT0044" ref-type="bibr">44</xref>,<xref rid="CIT0050" ref-type="bibr">50</xref>,<xref rid="CIT0051" ref-type="bibr">51</xref></sup> and (3) the acquisition of heroin-induced conditioned place preference.<sup><xref rid="CIT0037" ref-type="bibr">37</xref></sup> Additionally, the selective inhibition of heroin-related behaviors was observed while allowing the concurrent use of opioid analgesics such as codeine, buprenorphine, and methadone.<sup><xref rid="CIT0037" ref-type="bibr">37</xref></sup> The endpoints of these preclinical studies underscore the importance of vaccine formulations and adjuvants in influencing antibody titers and specificity.<sup><xref rid="CIT0052" ref-type="bibr">52</xref>,<xref rid="CIT0053" ref-type="bibr">53</xref></sup> Specifically, liposomes containing monophosphoryl lipid A and certain haptens such as DiAmHap and 6-PrOxyHap demonstrate their efficacy in enhancing antibody production and specificity.<sup><xref rid="CIT0052" ref-type="bibr">52-54</xref></sup> Furthermore, formulations with adjuvants, such as Toll-like receptor (TLR) agonists (TLR3 or TLR9) and alum prove to be robust inducers of anti-heroin antibody titers, protecting against heroin-induced antinociception.<sup><xref rid="CIT0055" ref-type="bibr">55</xref></sup> Moreover, Bremer et al. reported that their heroin vaccine elicited high titers of heroin-specific antibodies, leading to a significant reduction in the potency of heroin, an effect which was sustained after 3 rounds of vaccinations and persisted for over 8 months.<sup><xref rid="CIT0056" ref-type="bibr">56</xref></sup> Several studies also highlight the specificity of induced antibodies, with selectivity for heroin, 6-AM, and morphine, without cross-reactivity with other prescription opioids.<sup><xref rid="CIT0057" ref-type="bibr">57</xref>,<xref rid="CIT0058" ref-type="bibr">58</xref></sup> Notably, regioselective deuteration of a heroin-hapten (HdAc) has been shown to enhance vaccine efficacy in blocking heroin-induced antinociception, demonstrating the importance of hapten structure.<sup><xref rid="CIT0049" ref-type="bibr">49</xref></sup> The combination of the vaccine with naloxone prolongs the antagonism of morphine&#8217;s effects, suggesting potential synergy between vaccines and other interventions.<sup><xref rid="CIT0059" ref-type="bibr">59</xref></sup> Collectively, these preclinical studies demonstrate the potential therapeutic value of heroin vaccination in the treatment of OUD.<sup><xref rid="CIT0047" ref-type="bibr">47</xref>,<xref rid="CIT0054" ref-type="bibr">54</xref>,<xref rid="CIT0060" ref-type="bibr">60</xref>,<xref rid="CIT0061" ref-type="bibr">61</xref></sup></p><p>Unlike anti-nicotine and anti-cocaine vaccines, there is limited clinical data on opioid-specific vaccines, with only 3 published human clinical trials to date.<sup><xref rid="CIT0062" ref-type="bibr">62-64</xref></sup> In 2007, Akbarzadeh et al. reported a randomized double-blind placebo-controlled study, with 102 outpatient participants with OUD.<sup><xref rid="CIT0064" ref-type="bibr">64</xref></sup> The primary outcome of that trial demonstrated the safety and immunogenicity of a morphine vaccine. Patients received different doses of the morphine vaccine (12.5, 100, and 600 &#956;g/mL). Specifically, participants received 3 intramuscular injections at day 0, day 30, and day 60 and were monitored for safety and antibody production over 12 months. All 102 volunteers completed the 3-injection course, with antibody levels monitored at 5, 7, 9, 11, and 12 months. The vaccine demonstrated good tolerability, dose-dependent increases in antibody levels, and no serious adverse events. Local pain and tenderness at the injection site were the most common side effects. Anti-morphine antibodies were detected after the first and second injections, reaching peak levels at 3 months and persisting for at least 1 year. This study demonstrated that morphine vaccines were well-tolerated, induced robust antibody responses, and could provide an alternative strategy for preventing relapse.<sup><xref rid="CIT0064" ref-type="bibr">64</xref></sup></p><p>In 2009, the same group conducted another trial involving 347 individuals with OUD, exploring the tolerability, safety, and efficacy of the same morphine vaccine at a single dose (50 &#956;g/mL), which was administered 3 times on days 0, 30, and 60.<sup><xref rid="CIT0063" ref-type="bibr">63</xref></sup> The vaccine was well-tolerated and had fewer local side effects compared with other viral and bacterial vaccines. The enhancement was observed in anti-morphine antibody, total protein, and gamma globulin levels after the second and third vaccinations, peaking at 3 months but starting to decline by the fourth month. As anticipated, levels of anti-morphine antibodies were higher than baseline levels, even 1-year post-immunization. This study recommended re-vaccination within the first year.<sup><xref rid="CIT0063" ref-type="bibr">63</xref></sup> However, the clinical significance of these findings remains uncertain, as treatment-related outcomes and efficacy data are absent, leaving unanswered critical questions regarding the optimal dosing regimen and vaccine effectiveness.<sup><xref rid="CIT0062" ref-type="bibr">62</xref>,<xref rid="CIT0063" ref-type="bibr">63</xref></sup></p><p>In 2012, Farhangi et al. reported the synthesis and efficacy of a morphine vaccine through the conjugation of morphine-6-hemisuccinate with BSA.<sup><xref rid="CIT0062" ref-type="bibr">62</xref></sup> A cohort of 436 individuals with OUD received a regimen of 3 doses of the morphine vaccine administered over a 60-day period. Anti-morphine antibody levels in participants were measured on the 90th and 360th days. This morphine vaccine exhibited a sustained ability to prevent relapse. However, a decrease in anti-morphine antibody levels was observed 1 year after vaccination. This study emphasized the safety and efficacy of morphine vaccines, highlighting their favorable profile with fewer adverse effects than vaccines for many infectious diseases.<sup><xref rid="CIT0062" ref-type="bibr">62</xref></sup> Notably, approximately 90% of the patients with OUD who completed the study maintained sobriety.<sup><xref rid="CIT0062" ref-type="bibr">62</xref></sup> Despite the favorable outcomes observed in these studies, there remains a scarcity of efficacy data. Additionally, BSA is a major beef allergen and has the potential to cause allergic reactions, thereby limiting widespread, long-term use, or repeated exposures.<sup><xref rid="CIT0065" ref-type="bibr">65-67</xref></sup> More comprehensive research is needed regarding the optimal dosing regimen, subsequent relapse rates, and the effective range of the antibody titers.<sup><xref rid="CIT0062" ref-type="bibr">62</xref>,<xref rid="CIT0064" ref-type="bibr">64</xref></sup> Thus, future research is required to elucidate the safety, efficacy, and long-term impact of opioid vaccines in the treatment landscape of OUD.</p></sec><sec id="s3"><title>PRECLINICAL VACCINE STUDIES: TARGETING OXYCODONE AND HYDROCODONE</title><p>The overprescription of opioid analgesics in the United States has reached epidemic levels, posing a serious public health crisis.<sup><xref rid="CIT0068" ref-type="bibr">68</xref>,<xref rid="CIT0069" ref-type="bibr">69</xref></sup> In the United States, about 3% of individuals aged 12 or older (approximately 8.6 million people) misused prescription pain relievers in the past year, according to 2023 data.<sup><xref rid="CIT0034" ref-type="bibr">34</xref></sup>. Hydrocodone and oxycodone were the most misused prescription opioid pain relievers, accounting for 74.1% of misuse, while prescription fentanyl was misused by only 5.6% of individuals. Oxycodone was initially introduced to treat severe pain. However, its widespread availability and high abuse potential have led to a concerning trend of misuse and an increasing incidence of OUD, with many individuals transitioning to even more potent substances, such as fentanyl or heroin.<sup><xref rid="CIT0070" ref-type="bibr">70</xref>,<xref rid="CIT0071" ref-type="bibr">71</xref></sup> In 2018, the global usage of oxycodone, including both prescribed and illegal forms, hit a peak of 45&#8197;717 defined daily doses.<sup><xref rid="CIT0069" ref-type="bibr">69</xref></sup> This level of consumption positioned oxycodone as the second most commonly used opioid, following fentanyl.<sup><xref rid="CIT0069" ref-type="bibr">69</xref></sup> Moreover, the United States accounted for approximately 73% of the global consumption of oxycodone between 1996 and 2016, highlighting its extensive use.<sup><xref rid="CIT0072" ref-type="bibr">72</xref></sup></p><p>The preclinical opioid vaccine studies targeting oxycodone have shown positive outcomes, suggesting the potential efficacy and safety of vaccination in combating OUD (<xref rid="sup2" ref-type="supplementary-material">Table S2</xref>). Several studies have demonstrated that the oxycodone vaccine effectively diminishes the reinforcing effects of oxycodone,<sup><xref rid="CIT0073" ref-type="bibr">73-75</xref></sup> and significantly decreases the distribution of opioids to the brain, potentially mitigating their central effects.<sup><xref rid="CIT0074" ref-type="bibr">74</xref>,<xref rid="CIT0076" ref-type="bibr">76-81</xref></sup> Previous preclinical studies have highlighted a reduction in opioid-induced antinociception.<sup><xref rid="CIT0074" ref-type="bibr">74-76</xref>,<xref rid="CIT0082" ref-type="bibr">82</xref></sup> Specifically, these studies reported that high-titer antibodies specific for oxycodone were produced after vaccination.<sup><xref rid="CIT0075" ref-type="bibr">75</xref>,<xref rid="CIT0076" ref-type="bibr">76</xref>,<xref rid="CIT0083" ref-type="bibr">83-87</xref></sup> Vaccine-related toxicity or adverse effects were not observed,<sup><xref rid="CIT0085" ref-type="bibr">85</xref></sup> underscoring the safety and tolerability of the vaccine. Several studies suggest that the opioid vaccine may protect against overdose and fatality by reducing the opioid distribution to the brain and its subsequent effects.<sup><xref rid="CIT0074" ref-type="bibr">74</xref>,<xref rid="CIT0077" ref-type="bibr">77</xref>,<xref rid="CIT0078" ref-type="bibr">78</xref>,<xref rid="CIT0088" ref-type="bibr">88</xref>,<xref rid="CIT0089" ref-type="bibr">89</xref></sup> Vaccine efficacy was influenced by the dosage and administration route, with improved outcomes observed after subcutaneous administration compared to intravenous delivery.<sup><xref rid="CIT0090" ref-type="bibr">90</xref></sup> Common outcomes evaluated in studies targeting hydrocodone vaccines include the decrease of antinociceptive efficacy for both hydrocodone and oxycodone, as well as potential cross-reactivity in serum antibodies. These studies also reported sustained efficacy in attenuating opioid antinociceptive effects and improved survival rates against lethal doses of both opioids.<sup><xref rid="CIT0077" ref-type="bibr">77</xref>,<xref rid="CIT0089" ref-type="bibr">89</xref></sup></p></sec><sec id="s4"><title>PRECLINICAL VACCINE STUDIES: TARGETING FENTANYL, SYNTHETIC FENTANYL ANALOGS AND SYNTHETIC OPIOIDS</title><p>The US Centers for Disease Control and Prevention (CDC) reports that the United States is currently experiencing a &#8220;fourth wave&#8221; of opioid overdose deaths driven primarily by potent synthetic opioids , that is, fentanyl, carfentanil, and other synthetic fentanyl analogs.<sup><xref rid="CIT0032" ref-type="bibr">32</xref></sup> Carfentanil is a synthetic opioid. Its presence in illicit drug markets in the United States is alarming, as the potency of this drug could lead to an increase in overdoses and overdose-related deaths. Carfentanil is used as a sedative agent for elephants and other large mammals. Carfentanil is approximately 10&#8197;000 times more potent than morphine and 100 times more potent than fentanyl, which can be lethal at the 2-milligram range.<sup><xref rid="CIT0091" ref-type="bibr">91</xref></sup> While deaths from heroin and prescription opioids have remained relatively stable, fatalities involving synthetic opioids like fentanyl and carfentanil have dramatically increased in recent years.<sup><xref rid="CIT0092" ref-type="bibr">92</xref>,<xref rid="CIT0093" ref-type="bibr">93</xref></sup> These substances pose a unique challenge due to their high potency, rapid onset of action, and narrow therapeutic window, which may significantly increase the risk of overdose.<sup><xref rid="CIT0094" ref-type="bibr">94</xref>,<xref rid="CIT0095" ref-type="bibr">95</xref></sup> Notably, fentanyl and its analogs have been implicated in the majority of fatal opioid overdoses, surpassing other opioids in their lethality.<sup><xref rid="CIT0096" ref-type="bibr">96</xref>,<xref rid="CIT0097" ref-type="bibr">97</xref></sup> The CDC&#8217;s National Center for Health Statistics reported that opioid overdose deaths were estimated at 81&#8197;083 in 2023, with synthetic opioids, primarily fentanyl, associated with over 90% of these deaths.<sup><xref rid="CIT0094" ref-type="bibr">94</xref>,<xref rid="CIT0095" ref-type="bibr">95</xref>,<xref rid="CIT0098" ref-type="bibr">98</xref></sup> Fentanyl, originally developed for anesthesia and severe pain management, is now widely misused and has become a primary driver of opioid overdoses. Overdose due to illicit synthetic opioids (eg, fentanyl and fentanyl analogs) continues to rise.<sup><xref rid="CIT0032" ref-type="bibr">32</xref></sup> Illicitly manufactured fentanyl is often mixed with or sold as heroin. According to the Drug Enforcement Administration (DEA) laboratory testing, 6 out of 10 fentanyl-laced counterfeit prescription pills now contain a potentially lethal dose of fentanyl.<sup><xref rid="CIT0099" ref-type="bibr">99</xref></sup></p><p>The potency of fentanyl is approximately 50-100 times greater than that of morphine, which significantly increases the risk of overdose due to its ability to induce respiratory depression at much lower doses.<sup><xref rid="CIT0100" ref-type="bibr">100</xref>,<xref rid="CIT0101" ref-type="bibr">101</xref></sup> Carfentanil, a synthetic analog of fentanyl, is about 100 times more potent than fentanyl, meaning it can exert its effects at even smaller doses, thereby dramatically increasing the risk of fatal overdose.<sup><xref rid="CIT0102" ref-type="bibr">102</xref></sup> This extreme potency of fentanyl and carfentanil poses a significant challenge for overdose management, as even a slight miscalculation in dosage can lead to lethal outcomes. The high potency of these synthetic opioids not only raises the risk of accidental overdose but may also affect the efficacy of therapeutic interventions like opioid vaccines. Vaccines targeting these opioids need to generate sufficiently high titers of antibodies to effectively neutralize these potent compounds before they can reach the brain and exert their effects. The surge in overdoses involving these synthetic opioids underscores the urgent need for innovative strategies to prevent and treat OUD and overdose.<sup><xref rid="CIT0103" ref-type="bibr">103-105</xref></sup></p><p>Several preclinical studies have investigated vaccines for both fentanyl and synthetic fentanyl analogs. The main outcome measures were (1) a reduction in potency and reinforcing effects,<sup><xref rid="CIT0106" ref-type="bibr">106</xref>,<xref rid="CIT0107" ref-type="bibr">107</xref></sup> (2) levels of anti-fentanyl antibodies,<sup><xref rid="CIT0086" ref-type="bibr">86</xref>,<xref rid="CIT0108" ref-type="bibr">108-111</xref></sup> (3) blocking of fentanyl and synthetic fentanyl analog-induced antinociception,<sup><xref rid="CIT0108" ref-type="bibr">108</xref>,<xref rid="CIT0109" ref-type="bibr">109</xref>,<xref rid="CIT0111" ref-type="bibr">111-114</xref></sup> and (4) respiratory depression<sup><xref rid="CIT0109" ref-type="bibr">109</xref>,<xref rid="CIT0112" ref-type="bibr">112-115</xref></sup> (<xref rid="sup3" ref-type="supplementary-material">Table S3</xref>). These vaccines exhibited sustained efficacy over time<sup><xref rid="CIT0106" ref-type="bibr">106</xref></sup> and were effective in altering drug distribution to the brain, thereby reducing central nervous system effects.<sup><xref rid="CIT0087" ref-type="bibr">87</xref>,<xref rid="CIT0096" ref-type="bibr">96</xref>,<xref rid="CIT0114" ref-type="bibr">114</xref>,<xref rid="CIT0116" ref-type="bibr">116</xref></sup> Some vaccines demonstrated efficacy comparable to traditional opioid antagonist medications like naltrexone,<sup><xref rid="CIT0106" ref-type="bibr">106</xref>,<xref rid="CIT0107" ref-type="bibr">107</xref></sup> with the onset of vaccine action sometimes being slower but displaying prolonged duration compared to standard treatments.<sup><xref rid="CIT0117" ref-type="bibr">117</xref></sup> Additionally, the vaccines demonstrated high selectivity by not interfering with the pharmacological activity of other opioids such as oxycodone, heroin, or methadone.<sup><xref rid="CIT0113" ref-type="bibr">113</xref></sup> A recent vaccine preclinical trial against U-47700, a synthetic opioid, demonstrated the vaccine&#8217;s ability to alter drug distribution, leading to substantial drug retention in the bloodstream and reducing diffusion into the brain.<sup><xref rid="CIT0118" ref-type="bibr">Park et al., 2023</xref></sup> Benzimidazole opioids, also known as nitazenes, are a group of new psychoactive substances that have recently led to an increase in fatal overdoses in the United States and Europe.<sup><xref rid="CIT0119" ref-type="bibr">119</xref></sup> These opioids have emerged in the illicit drug market, posing a growing public health threat. A recent preclinical study of a vaccine targeting benzimidazole-derived new psychoactive substance opioids (BNO) demonstrated its efficacy in generating robust antibody responses against various BNO drugs.<sup><xref rid="CIT0120" ref-type="bibr">120</xref></sup> That vaccine also effectively mitigated opioid molecules crossing the blood-brain barrier, opioid-induced respiratory depression, and opioid-induced antinociception.<sup><xref rid="CIT0120" ref-type="bibr">120</xref></sup> These findings collectively underscore the potential of vaccines as a novel approach to mitigate the effects of fentanyl and its analogs.</p></sec><sec id="s5"><title>BIVALENT OPIOID VACCINES</title><p>The opioid crisis has also led to a concerning rise in poly-opioid use, particularly due to the addition of potent synthetic opioids, such as fentanyl to street heroin.<sup><xref rid="CIT0104" ref-type="bibr">104</xref>,<xref rid="CIT0121" ref-type="bibr">121-123</xref></sup> This combination exacerbates respiratory depression and increases the risk of overdose and death. Recent studies have shown that fentanyl contamination of heroin can drastically increase the risk of overdose due to fentanyl&#8217;s high potency and its potential to induce severe respiratory depression, leading to enhanced brain hypoxia.<sup><xref rid="CIT0124" ref-type="bibr">124</xref></sup> Researchers are exploring bivalent vaccines, which contain structurally different immunoconjugates to target multiple opioids simultaneously. These vaccines exhibit promising efficacy in conferring protection against the use of multiple opioids, a prevalent contemporary challenge.<sup><xref rid="CIT0014" ref-type="bibr">14</xref></sup> With the surge in overdose cases linked to fentanyl-contaminated heroin, the development of multivalent vaccines may be an innovative approach to combating opioid overdose and OUD by targeting multiple opioids with distinct chemical structures.<sup><xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0017" ref-type="bibr">17</xref></sup> Since opioid users often engage in concurrent use of multiple opioids or transition between different opioids, a multivalent vaccine strategy might offer a more effective solution, potentially conferring long-lasting protection against overdose and relapse.<sup><xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0017" ref-type="bibr">17</xref>,<xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0125" ref-type="bibr">125</xref></sup></p><p>Bivalent vaccines combining heroin and fentanyl antigens showed efficacy in reducing opioid-induced antinociception, indicating potential synergistic effects in preclinical studies<sup><xref rid="CIT0126" ref-type="bibr">126-128</xref></sup> (<xref rid="sup4" ref-type="supplementary-material">Table S4</xref>). These vaccines elicited potent antibody responses, effectively reducing the distribution of opioids in the brain, thus mitigating their central effects.<sup><xref rid="CIT0127" ref-type="bibr">127</xref>,<xref rid="CIT0129" ref-type="bibr">129-131</xref></sup> The bivalent vaccine formulations exhibited strong binding capabilities against a range of opioids, including heroin, fentanyl, and oxycodone, as well as their mixtures, demonstrating broad-spectrum protection.<sup><xref rid="CIT0132" ref-type="bibr">132-134</xref></sup> In addition, lyophilized vaccine formulations have maintained their effectiveness for up to a year when stored at room temperature.<sup><xref rid="CIT0129" ref-type="bibr">129</xref></sup> It has been reported that a dual fentanyl/heroin vaccine did not affect the antinociceptive potency of methadone, highlighting the vaccine&#8217;s selective efficacy. This result suggests that combining methadone with the vaccine could be beneficial for treating OUD and managing pain.<sup><xref rid="CIT0132" ref-type="bibr">132</xref></sup> Overall, these findings underscore the possible value of bivalent vaccination strategies for mitigating the harmful effects of opioids, paving the way for further clinical development and evaluation. Currently, a phase I/II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04458545">NCT04458545</ext-link>) is ongoing in the United States. This trial was designed to evaluate the safety and efficacy of reducing opioid use, the magnitude of antibody responses, and the efficacy of a bivalent vaccine targeting oxycodone and heroin.</p></sec><sec id="s6"><title>CONCLUSIONS AND FUTURE PERSPECTIVES</title><p>The development of vaccines against OUD presents a novel approach for addressing the challenges associated with existing treatment approaches. Opioid vaccines may be beneficial for some patients due to their capacity to provide prolonged protection, fewer side effects, high selectivity, and reduced misuse potential. Opioid vaccines do not target the FDA-approved pharmacotherapies, such as methadone, buprenorphine, and naltrexone. Thus, the concurrent use of these medications alongside the vaccine underscores its potential benefits. A key advantage of opioid vaccines is their selective effectiveness in blocking the effects of substances like fentanyl and heroin, while leaving medications that act on the &#956;-opioid receptor unaffected.</p><p>Although vaccine treatment studies for OUD have been known for more than 50 years, there is still no effective vaccine available for clinical implementation. Despite the promising aspects which we have outlined here, there are also challenges. First, patients with OUD generally do not use a single type of opioid, rather, they often use multiple opioids or other substances simultaneously, such as stimulants.<sup><xref rid="CIT0135" ref-type="bibr">135</xref></sup> The use of multiple substances at varying doses in heterogeneous cocktails raises questions regarding the appropriate vaccine choice. Second, the optimal schedule of inoculations, the recommended frequency of boosters, and the effective range of antibody titers all remain unanswered. Individual variability in antibody titers and the potential for substitution of different drugs pose challenges, especially for compounds with small molecular weights that may not be recognized by the immune system. Finally, individuals may choose different opioids that are not targeted by the vaccine to achieve the desired euphoric effects or try to override the protective effects of the vaccine by using higher doses of opioids. It should be noted that vaccines alone may not alleviate craving, which is one of the critical factors for relapse. Vaccines against opioids produce antibodies that neutralize opioids, preventing them from crossing the blood-brain barrier and diminishing their psychoactive effects. In addition to preventing relapse, vaccines could potentially save lives by offering protection in cases of relapse involving highly potent opioids. OUD has a neurobiological component that involves tolerance, withdrawal, and craving. However, it remains unclear whether opioid vaccines can influence these aspects. More human clinical research will be required to assess the safety, efficacy, and long-term impact of opioid vaccines. Future research will also need to address concerns with regard to the heterogeneity of immune responses, the implementation of multivalent strategies for both multi-opioid and diverse substance use, and the acceptance by diverse populations.</p><p>Furthermore, the ethical landscape surrounding opioid vaccines is intricate and multifaceted.<sup><xref rid="CIT0136" ref-type="bibr">136</xref></sup> Key concerns revolve around the voluntary vs mandatory use of vaccines, the prioritization of vulnerable and marginalized groups, and the ethical implications of prophylactic vaccination.<sup><xref rid="CIT0137" ref-type="bibr">137-139</xref></sup> Integrating opioid vaccines into existing treatment protocols necessitates careful management to mitigate unintended health disparities, particularly in scenarios involving pain management.<sup><xref rid="CIT0136" ref-type="bibr">136</xref>,<xref rid="CIT0138" ref-type="bibr">138</xref></sup> Opioid vaccines typically stimulate a sustained antibody response by activating the immune system, with the potential for cross-reactivity among different opioids. However, most opioid vaccine studies emphasize selectivity as a primary objective. This raises ethical concerns regarding the duration of the vaccine&#8217;s effects, particularly if patients might later require opioid-based pain relief or emergency surgery. <xref rid="CIT0140" ref-type="bibr">Weitzman et al., 2024</xref> Furthermore, it is possible that the implementation of specific opioid-targeting vaccines, that is, heroin in patients with OUD, may inadvertently drive individuals toward more potent and dangerous substances like fentanyl analogs to achieve euphoric effects.<sup><xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0139" ref-type="bibr">139</xref></sup> It is an open question whether patients with immune deficiency-related diseases should be vaccinated. Given that long-term opioid use is associated with immune insufficiency, the effectiveness of vaccination is unclear. The ethical issue of involuntary administration raises significant concerns regarding personal autonomy and informed consent. That issue is particularly contentious if mandates are considered for individuals in the justice system, pregnant women, or parents involved in child welfare disputes.<sup><xref rid="CIT0137" ref-type="bibr">137</xref>,<xref rid="CIT0138" ref-type="bibr">138</xref>,<xref rid="CIT0141" ref-type="bibr">141</xref></sup> Ensuring the safety and efficacy of these interventions in voluntary settings is essential before contemplating their mandatory use. Ethical deliberations must carefully weigh the potential benefits of reducing relapse against the risks of violating individual rights and autonomy, underscoring the complexity of integrating opioid vaccines into public health strategies. These issues highlight the complexities and ethical nuances inherent in the development, deployment, and implementation of opioid vaccines.</p><p>In conclusion, while MOUD is effective, its benefits may be limited by poor adherence to treatment recommendations. Therefore, a complementary approach, such as vaccine-based treatment, could serve as an additional option during the ongoing opioid crisis. Immunotherapies arouse great interest as a &#8220;hot topic&#8221; in the treatment of many psychiatric diseases such as schizophrenia,<sup><xref rid="CIT0142" ref-type="bibr">142</xref></sup> depression,<sup><xref rid="CIT0143" ref-type="bibr">143</xref></sup> obsessive-compulsive disorder<sup><xref rid="CIT0144" ref-type="bibr">144</xref></sup> and autism.<sup><xref rid="CIT0145" ref-type="bibr">145</xref>,<xref rid="CIT0146" ref-type="bibr">146</xref></sup> The use of vaccines to treat substance use disorders is one of the most dynamic and actively researched areas in the field. There is a clear potential that opioid vaccines could be a novel alternative treatment approach for OUD and overdose prevention. However, for the reasons mentioned above, it is highly unlikely that vaccine therapy will be a definitive cure or the sole treatment for OUD. Despite the challenges, opioid immunotherapy presents a potentially impactful treatment strategy during the ongoing opioid epidemic, offering potential benefits in overdose prevention and OUD treatment. However, extensive research and careful ethical consideration are needed to fully develop and implement this potential therapeutic approach.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>pyaf005_suppl_Supplementary_Table_S1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pyaf005_suppl_supplementary_table_s1.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sup2" position="float" content-type="local-data" orientation="portrait"><label>pyaf005_suppl_Supplementary_Table_S2</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pyaf005_suppl_supplementary_table_s2.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sup3" position="float" content-type="local-data" orientation="portrait"><label>pyaf005_suppl_Supplementary_Table_S3</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pyaf005_suppl_supplementary_table_s3.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sup4" position="float" content-type="local-data" orientation="portrait"><label>pyaf005_suppl_Supplementary_Table_S4</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pyaf005_suppl_supplementary_table_s4.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="a1"><title>Acknowledgments</title><p>We extend our sincere gratitude to Dr Leila Jones for providing administrative support for our addiction research program.</p></ack><sec id="s8"><title>Author contributions</title><p>Mustafa Tuncturk (Writing&#8212;original draft [equal]), Shikha Kushwaha (Writing&#8212;review &amp; editing [equal]), Robin M. Heider (Writing&#8212;review &amp; editing [equal]), Tyler Oesterle (Writing&#8212;review &amp; editing [equal]), Richard Weinshilboum (Writing&#8212;review &amp; editing [equal]), and Ming-Fen Ho (Conceptualization [equal], Supervision [equal], Writing&#8212;original draft [equal], Writing&#8212;review &amp; editing [equal])</p></sec><sec id="s9"><title>Funding</title><p>This work was supported in part by the National Institutes of Health [grant numbers: R01 DA57928, K01 AA28050, R01 AA27486, and R18 HS29774]; the Brain &amp; Behavior Research Foundation [grant number: 31329], the Mayo Clinic Research Pipeline K2R Program, the Terrance and Bette Noble Foundation, and the Mayo Clinic Center for Individualized Medicine.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflicts of interest</title><p>Dr Weinshilboum is a cofounder of and stockholder in OneOme LLC, a pharmacogenomics decision-support company. All other authors have no conflicts to declare.</p></sec><sec sec-type="data-availability" id="s11"><title>Data availability</title><p>No new data were generated or analyzed in support of this research.</p></sec><ref-list id="r1"><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Florence</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rice</surname><given-names>K.</given-names></string-name></person-group><article-title>The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017</article-title>. <source>Drug Alcohol Depend.</source><year>2021</year>; <volume>218</volume>:<fpage>108350</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.108350</pub-id><pub-id pub-id-type="pmid">33121867</pub-id><pub-id pub-id-type="pmcid">PMC8091480</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Grebely</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Stone</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Global patterns of opioid use and dependence: harms to populations, interventions, and future action</article-title>. <source>Lancet.</source><year>2019</year>; <volume>394</volume>:<fpage>1560</fpage>&#8211;<lpage>1579</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/S0140-6736(19)32229-9</pub-id><pub-id pub-id-type="pmid">31657732</pub-id><pub-id pub-id-type="pmcid">PMC7068135</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oesterle</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Thusius</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Rummans</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Gold</surname><given-names>MS.</given-names></string-name></person-group><article-title>Medication-assisted treatment for opioid-use disorder</article-title>. <source>Mayo Clin Proc.</source><year>2019</year>; <volume>94</volume>:<fpage>2072</fpage>&#8211;<lpage>2086</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.mayocp.2019.03.029</pub-id><pub-id pub-id-type="pmid">31543255</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mauro</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Gutkind</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Annunziato</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Samples</surname><given-names>H.</given-names></string-name></person-group><article-title>Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019</article-title>. <source>JAMA Netw Open.</source><year>2022</year>; <volume>5</volume>:<fpage>e223821</fpage>&#8211;<lpage>e223821</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.3821</pub-id><pub-id pub-id-type="pmid">35319762</pub-id><pub-id pub-id-type="pmcid">PMC8943638</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maglione</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Raaen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal><article-title>Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: a systematic review</article-title>. <source>J Subst Abuse Treat.</source><year>2018</year>; <volume>89</volume>:<fpage>28</fpage>&#8211;<lpage>51</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.jsat.2018.03.001</pub-id><pub-id pub-id-type="pmid">29706172</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koehl</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Zimmerman</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Bridgeman</surname><given-names>PJ.</given-names></string-name></person-group><article-title>Medications for management of opioid use disorder</article-title>. <source>Am J Health Syst Pharm.</source><year>2019</year>; <volume>76</volume>:<fpage>1097</fpage>&#8211;<lpage>1103</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1093/ajhp/zxz105</pub-id><pub-id pub-id-type="pmid">31361869</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coffa</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Snyder</surname><given-names>H.</given-names></string-name></person-group><article-title>Opioid use disorder: medical treatment options</article-title>. <source>Am Fam Physician.</source><year>2019</year>; <volume>100</volume>:<fpage>416</fpage>&#8211;<lpage>425</lpage>.<pub-id pub-id-type="pmid">31573166</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shaw</surname><given-names>LV</given-names></string-name>, <string-name name-style="western"><surname>Moe</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Purssell</surname><given-names>R</given-names></string-name></person-group>, <etal>et al</etal><article-title>Naloxone interventions in opioid overdoses: a systematic review protocol</article-title>. <source>Syst Rev.</source><year>2019</year>; <volume>8</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31186071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13643-019-1048-y</pub-id><pub-id pub-id-type="pmcid">PMC6560883</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crystal</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ellison</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Purdon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Skolnick</surname><given-names>P.</given-names></string-name></person-group><article-title>Pharmacokinetic properties of an FDA&#8208;approved intranasal nalmefene formulation for the treatment of opioid overdose</article-title>. <source>Clin Pharmacol Drug Dev.</source><year>2024</year>; <volume>13</volume>:<fpage>58</fpage>&#8211;<lpage>69</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1002/cpdd.1312</pub-id><pub-id pub-id-type="pmid">37496452</pub-id><pub-id pub-id-type="pmcid">PMC10818017</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Velander</surname><given-names>JR.</given-names></string-name></person-group><article-title>Suboxone: rationale, science, misconceptions</article-title>. <source>Ochsner J.</source><year>2018</year>; <volume>18</volume>:<fpage>23</fpage>&#8211;<lpage>29</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.121</pub-id><pub-id pub-id-type="pmid">29559865</pub-id><pub-id pub-id-type="pmcid">PMC5855417</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weiss</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Potter</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Fiellin</surname><given-names>DA</given-names></string-name></person-group>, <etal>et al</etal><article-title>Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial</article-title>. <source>Arch Gen Psychiatry.</source><year>2011</year>; <volume>68</volume>:<fpage>1238</fpage>&#8211;<lpage>1246</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.121</pub-id><pub-id pub-id-type="pmid">22065255</pub-id><pub-id pub-id-type="pmcid">PMC3470422</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bailey</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Herman</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>MD.</given-names></string-name></person-group><article-title>Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification</article-title>. <source>J Subst Abuse Treat.</source><year>2013</year>; <volume>45</volume>:<fpage>302</fpage>&#8211;<lpage>305</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.jsat.2013.04.002</pub-id><pub-id pub-id-type="pmid">23786852</pub-id><pub-id pub-id-type="pmcid">PMC4874241</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Celik</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fuehrlein</surname><given-names>B.</given-names></string-name></person-group><article-title>A review of immunotherapeutic approaches for substance use disorders: current status and future prospects</article-title>. <source>Immunotargets Ther</source>. <year>2022</year>; <volume>11</volume>:<fpage>55</fpage>&#8211;<lpage>66</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.2147/itt.s370435</pub-id><pub-id pub-id-type="pmid">36199734</pub-id><pub-id pub-id-type="pmcid">PMC9528911</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Comer</surname><given-names>SD.</given-names></string-name></person-group><article-title>Development of vaccines to treat opioid use disorders and reduce incidence of overdose</article-title>. <source>Neuropharmacology.</source><year>2019</year>; <volume>158</volume>:<fpage>107662</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.06.001</pub-id><pub-id pub-id-type="pmid">31173759</pub-id><pub-id pub-id-type="pmcid">PMC6919211</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bonese</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wainer</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Fitch</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rothberg</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schuster</surname><given-names>C.</given-names></string-name></person-group><article-title>Changes in heroin self-administration by a rhesus monkey after morphine immunisation</article-title>. <source>Nature.</source><year>1974</year>; <volume>252</volume>:<fpage>708</fpage>&#8211;<lpage>710</lpage>.<pub-id pub-id-type="pmid">4474602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/252708a0</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kinsey</surname><given-names>B.</given-names></string-name></person-group><article-title>Vaccines against drugs of abuse: where are we now</article-title>? <source>Ther Adv Vaccines.</source><year>2014</year>; <volume>2</volume>:<fpage>106</fpage>&#8211;<lpage>117</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1177/2051013614537818</pub-id><pub-id pub-id-type="pmid">24982760</pub-id><pub-id pub-id-type="pmcid">PMC4063243</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Olson</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Janda</surname><given-names>KD.</given-names></string-name></person-group><article-title>Vaccines to combat the opioid crisis: vaccines that prevent opioids and other substances of abuse from entering the brain could effectively treat addiction and abuse</article-title>. <source>EMBO Rep.</source><year>2018</year>; <volume>19</volume>:<fpage>5</fpage>&#8211;<lpage>9</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.15252/embr.201745322</pub-id><pub-id pub-id-type="pmid">29237715</pub-id><pub-id pub-id-type="pmcid">PMC5757212</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scendoni</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bury</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ribeiro</surname><given-names>ILA</given-names></string-name>, <string-name name-style="western"><surname>Cameriere</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cingolani</surname><given-names>M.</given-names></string-name></person-group><article-title>Vaccines as a preventive tool for substance use disorder: a systematic review including a meta-analysis on nicotine vaccines&#8217; immunogenicity</article-title>. <source>Hum Vaccin Immunother.</source><year>2022</year>; <volume>18</volume>:<fpage>2140552</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1080/21645515.2022.2140552</pub-id><pub-id pub-id-type="pmid">36351881</pub-id><pub-id pub-id-type="pmcid">PMC9746524</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hossain</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Davidson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kypreos</surname><given-names>E</given-names></string-name></person-group>, <etal>et al</etal><article-title>Immunotherapies for the treatment of drug addiction</article-title>. <source>Vaccines.</source><year>2022</year>; <volume>10</volume>:<fpage>1778</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.3390/vaccines10111778</pub-id><pub-id pub-id-type="pmid">36366287</pub-id><pub-id pub-id-type="pmcid">PMC9697687</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huseby Kelcher</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Baehr</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Hamid</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname><given-names>GT</given-names></string-name>, <string-name name-style="western"><surname>Pravetoni</surname><given-names>M.</given-names></string-name></person-group><article-title>Contribution of antibody-mediated effector functions to the mechanism of efficacy of vaccines for opioid use disorders</article-title>. <source>J Immunol.</source><year>2021</year>; <volume>207</volume>:<fpage>860</fpage>&#8211;<lpage>867</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.4049/jimmunol.2100204</pub-id><pub-id pub-id-type="pmid">34281999</pub-id><pub-id pub-id-type="pmcid">PMC8324535</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luba</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Comer</surname><given-names>SD.</given-names></string-name></person-group><article-title>Immunotherapeutic strategies for treating opioid use disorder and overdose</article-title>. <source>Expert Opin Investig Drugs.</source><year>2023</year>; <volume>32</volume>:<fpage>77</fpage>&#8211;<lpage>87</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1080/13543784.2023.2173062</pub-id><pub-id pub-id-type="pmcid">PMC10035039</pub-id><pub-id pub-id-type="pmid">36696567</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hicks</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Baehr</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Silva-Ortiz</surname><given-names>P</given-names></string-name></person-group>, <etal>et al</etal><article-title>Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development</article-title>. <source>Hum Vaccin Immunother.</source><year>2022</year>; <volume>18</volume>:<fpage>2122507</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1080/21645515.2022.2122507</pub-id><pub-id pub-id-type="pmid">36194773</pub-id><pub-id pub-id-type="pmcid">PMC9746415</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smith</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>CS</given-names></string-name></person-group>, <etal>et al</etal><article-title>Monoclonal antibodies for combating synthetic opioid intoxication</article-title>. <source>J Am Chem Soc.</source><year>2019</year>; <volume>141</volume>:<fpage>10489</fpage>&#8211;<lpage>10503</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/jacs.9b04872</pub-id><pub-id pub-id-type="pmid">31187995</pub-id><pub-id pub-id-type="pmcid">PMC6662938</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baehr</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Pandit</surname><given-names>SG</given-names></string-name></person-group>, <etal>et al</etal><article-title>Pharmacological profiling of antifentanyl monoclonal antibodies in combination with naloxone in pre- and postexposure models of fentanyl toxicity</article-title>. <source>J Pharmacol Exp Ther.</source><year>2022</year>; <volume>381</volume>:<fpage>129</fpage>&#8211;<lpage>136</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1124/jpet.121.001048</pub-id><pub-id pub-id-type="pmid">35153198</pub-id><pub-id pub-id-type="pmcid">PMC9048265</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Banks</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Olson</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Janda</surname><given-names>KD.</given-names></string-name></person-group><article-title>Immunopharmacotherapies for treating opioid use disorder</article-title>. <source>Trends Pharmacol Sci.</source><year>2018</year>; <volume>39</volume>:<fpage>908</fpage>&#8211;<lpage>911</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.tips.2018.08.001</pub-id><pub-id pub-id-type="pmid">30343725</pub-id><pub-id pub-id-type="pmcid">PMC6472257</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Townsend</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Banks</surname><given-names>ML.</given-names></string-name></person-group><article-title>Preclinical evaluation of vaccines to treat opioid use disorders: how close are we to a clinically viable therapeutic</article-title>? <source>CNS Drugs.</source><year>2020</year>; <volume>34</volume>:<fpage>449</fpage>&#8211;<lpage>461</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1007/s40263-020-00722-8</pub-id><pub-id pub-id-type="pmid">32248427</pub-id><pub-id pub-id-type="pmcid">PMC7223115</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kosten</surname><given-names>TR.</given-names></string-name></person-group><article-title>Current status of immunotherapies for addiction</article-title>. <source>Ann N Y Acad Sci.</source><year>2021</year>; <volume>1489</volume>:<fpage>3</fpage>&#8211;<lpage>16</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1111/nyas.14329</pub-id><pub-id pub-id-type="pmid">32147860</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De</surname><given-names>BP</given-names></string-name>, <string-name name-style="western"><surname>Pagovich</surname><given-names>OE</given-names></string-name>, <string-name name-style="western"><surname>Hicks</surname><given-names>MJ</given-names></string-name></person-group>, <etal>et al</etal><article-title>Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity</article-title>. <source>Hum Gene Ther.</source><year>2013</year>; <volume>24</volume>:<fpage>58</fpage>&#8211;<lpage>66</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1089/hum.2012.163</pub-id><pub-id pub-id-type="pmid">23140508</pub-id><pub-id pub-id-type="pmcid">PMC3555097</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name></person-group>, <etal>et al</etal><article-title>Vaccines to treat substance use disorders: current status and future directions</article-title>. <source>Pharmaceutics.</source><year>2024</year>; <volume>16</volume>:<fpage>84</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.3390/pharmaceutics16010084</pub-id><pub-id pub-id-type="pmid">38258095</pub-id><pub-id pub-id-type="pmcid">PMC10820210</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Truong</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Kosten</surname><given-names>TR.</given-names></string-name></person-group><article-title>Current status of vaccines for substance use disorders: a brief review of human studies</article-title>. <source>J Neurol Sci.</source><year>2022</year>; <volume>434</volume>:<fpage>120098</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.jns.2021.120098</pub-id><pub-id pub-id-type="pmid">34952345</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Janda</surname><given-names>KD.</given-names></string-name></person-group><article-title>Conjugate vaccine immunotherapy for substance use disorder</article-title>. <source>Pharmacol Rev.</source><year>2017</year>; <volume>69</volume>:<fpage>298</fpage>&#8211;<lpage>315</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1124/pr.117.013904</pub-id><pub-id pub-id-type="pmid">28634286</pub-id><pub-id pub-id-type="pmcid">PMC5482184</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ciccarone</surname><given-names>D.</given-names></string-name></person-group><article-title>The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis</article-title>. <source>Curr Opin Psychiatry.</source><year>2021</year>; <volume>34</volume>:<fpage>344</fpage>&#8211;<lpage>350</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1097/YCO.0000000000000717</pub-id><pub-id pub-id-type="pmid">33965972</pub-id><pub-id pub-id-type="pmcid">PMC8154745</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33.</label><mixed-citation publication-type="journal"><collab>Substance Abuse and Mental Health Services Administration</collab>. Key substance use and mental health indicators in the United States: results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. <year>2023</year>. Accessed <comment>June 4, 2024</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report" ext-link-type="uri">https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report</ext-link></mixed-citation></ref><ref id="CIT0034"><label>34.</label><mixed-citation publication-type="journal"><collab>Substance Abuse and Mental Health Services Administration</collab>. Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH Series H-59). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. <year>2024</year>. Accessed <comment>November 5, 2024</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/data/report/2023-nsduh-annual-national-report" ext-link-type="uri">https://www.samhsa.gov/data/report/2023-nsduh-annual-national-report</ext-link></mixed-citation></ref><ref id="CIT0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rook</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Huitema</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>van den Brink</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>van Ree</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Beijnen</surname><given-names>JH.</given-names></string-name></person-group><article-title>Population pharmacokinetics of heroin and its major metabolites</article-title>. <source>Clin Pharmacokinet.</source><year>2006</year>; <volume>45</volume>:<fpage>401</fpage>&#8211;<lpage>417</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.2165/00003088-200645040-00005</pub-id><pub-id pub-id-type="pmid">16584286</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Neil Stowe</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Schlosburg J</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Vendruscolo L</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>Developing a vaccine against multiple psychoactive targets: a case study of heroin</article-title>. <source>CNS Neurol Disord Drug Targets.</source><year>2011</year>; <volume>10</volume>:<fpage>865</fpage>&#8211;<lpage>875</lpage>.<pub-id pub-id-type="pmid">22229311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/187152711799219316</pub-id><pub-id pub-id-type="pmcid">PMC3327724</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schlosburg</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Vendruscolo</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name></person-group>, <etal>et al</etal><article-title>Dynamic vaccine blocks relapse to compulsive intake of heroin</article-title>. <source>Proc Natl Acad Sci USA.</source><year>2013</year>; <volume>110</volume>:<fpage>9036</fpage>&#8211;<lpage>9041</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1073/pnas.1219159110</pub-id><pub-id pub-id-type="pmid">23650354</pub-id><pub-id pub-id-type="pmcid">PMC3670323</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wainer</surname><given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Fitch</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Rothberg</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Fried</surname><given-names>J.</given-names></string-name></person-group><article-title>Morphine-3-succinyl&#8212;bovine serum albumin: an immunogenic hapten-protein conjugate</article-title>. <source>Science.</source><year>1972</year>; <volume>176</volume>:<fpage>1143</fpage>&#8211;<lpage>1145</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1126/science.176.4039.1143</pub-id><pub-id pub-id-type="pmid">5064326</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hill</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Wainer</surname><given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Fitch</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Rothberg</surname><given-names>RM.</given-names></string-name></person-group><article-title>Delayed clearance of morphine from the circulation of rabbits immunized with morphine-6-hemisuccinate bovine serum albumin</article-title>. <source>J Immunol.</source><year>1975</year>; <volume>114</volume>:<fpage>1363</fpage>&#8211;<lpage>1368</lpage>.<pub-id pub-id-type="pmid">1117142</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Berkowitz</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Spector</surname><given-names>S.</given-names></string-name></person-group><article-title>Evidence for active immunity to morphine in mice</article-title>. <source>Science.</source><year>1972</year>; <volume>178</volume>:<fpage>1290</fpage>&#8211;<lpage>1292</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1126/science.178.4067.1290</pub-id><pub-id pub-id-type="pmid">4640066</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akbarzadeh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mehraby</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zarbakhsh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Farzaneh</surname><given-names>H.</given-names></string-name></person-group><article-title>Design and synthesis of a morphine&#8208;6&#8208;succinyl&#8208;bovine serum albumin hapten for vaccine development</article-title>. <source>Biotechnol Appl Biochem.</source><year>1999</year>; <volume>30</volume>:<fpage>139</fpage>&#8211;<lpage>146</lpage>.<pub-id pub-id-type="pmid">10512793</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kosten</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Malley</surname><given-names>PW</given-names></string-name></person-group>, <etal>et al</etal><article-title>A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry.</source><year>2013</year>; <volume>45</volume>:<fpage>223</fpage>&#8211;<lpage>229</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.05.012</pub-id><pub-id pub-id-type="pmid">23739535</pub-id><pub-id pub-id-type="pmcid">PMC3773503</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farhangi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Akbarzadeh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mehrabi</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal><article-title>Safety of human therapeutic morphine vaccine employing Lohmann specific pathogen free eggs</article-title>. <source>Pak J Biol Sci.</source><year>2010</year>; <volume>13</volume>:<fpage>1047</fpage>&#8211;<lpage>1051</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.3923/pjbs.2010.1047.1051</pub-id><pub-id pub-id-type="pmid">21313876</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raleigh</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Birnbaum</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Pentel</surname><given-names>PR.</given-names></string-name></person-group><article-title>Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats</article-title>. <source>J Pharmacol Exp Ther.</source><year>2013</year>; <volume>344</volume>:<fpage>397</fpage>&#8211;<lpage>406</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1124/jpet.112.201194</pub-id><pub-id pub-id-type="pmid">23220743</pub-id><pub-id pub-id-type="pmcid">PMC3558830</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raleigh</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Pentel</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>LeSage</surname><given-names>MG.</given-names></string-name></person-group><article-title>Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats</article-title>. <source>PLoS One.</source><year>2014</year>; <volume>9</volume>:<fpage>e115696</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1371/journal.pone.0115696</pub-id><pub-id pub-id-type="pmid">25536404</pub-id><pub-id pub-id-type="pmcid">PMC4275252</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Belz</surname><given-names>TF</given-names></string-name>, <string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal><article-title>Sulfonate-isosteric replacement examined within heroin-hapten vaccine design</article-title>. <source>Bioorg Med Chem Lett.</source><year>2020</year>; <volume>30</volume>:<fpage>127388</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127388</pub-id><pub-id pub-id-type="pmid">32738981</pub-id><pub-id pub-id-type="pmcid">PMC7398700</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stowe</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Vendruscolo</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>A vaccine strategy that induces protective immunity against heroin</article-title>. <source>J Med Chem.</source><year>2011</year>; <volume>54</volume>:<fpage>5195</fpage>&#8211;<lpage>5204</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/jm200461m</pub-id><pub-id pub-id-type="pmid">21692508</pub-id><pub-id pub-id-type="pmcid">PMC3142939</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Schlosburg</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Lively</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Janda</surname><given-names>KD.</given-names></string-name></person-group><article-title>Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy</article-title>. <source>Mol Pharm.</source><year>2014</year>; <volume>11</volume>:<fpage>1075</fpage>&#8211;<lpage>1080</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/mp400631w</pub-id><pub-id pub-id-type="pmid">24517171</pub-id><pub-id pub-id-type="pmcid">PMC3993894</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Belz</surname><given-names>TF</given-names></string-name>, <string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal><article-title>Enhancement of a heroin vaccine through hapten deuteration</article-title>. <source>J Am Chem Soc.</source><year>2020</year>; <volume>142</volume>:<fpage>13294</fpage>&#8211;<lpage>13298</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/jacs.0c05219</pub-id><pub-id pub-id-type="pmid">32700530</pub-id><pub-id pub-id-type="pmcid">PMC7544008</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M&#233;ndez</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Matus-Ortega</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Miramontes</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Salazar-Ju&#225;rez</surname><given-names>A.</given-names></string-name></person-group><article-title>The effect of chronic stress on the immunogenicity and immunoprotection of the M6-TT vaccine in female mice</article-title>. <source>Physiol Behav.</source><year>2023</year>; <volume>271</volume>:<fpage>114345</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.physbeh.2023.114345</pub-id><pub-id pub-id-type="pmid">37704173</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sulima</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jalah</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Antoline</surname><given-names>JF</given-names></string-name></person-group>, <etal>et al</etal><article-title>A stable heroin analogue that can serve as a vaccine hapten to induce antibodies that block the effects of heroin and its metabolites in rodents and that cross-react immunologically with related drugs of abuse</article-title>. <source>J Med Chem.</source><year>2018</year>; <volume>61</volume>:<fpage>329</fpage>&#8211;<lpage>343</lpage>.<pub-id pub-id-type="pmid">29236495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.7b01427</pub-id><pub-id pub-id-type="pmcid">PMC5767880</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Rice</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal><article-title>Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine</article-title>. <source>Vaccine.</source><year>2014</year>; <volume>32</volume>:<fpage>1473</fpage>&#8211;<lpage>1479</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.01.028</pub-id><pub-id pub-id-type="pmid">24486371</pub-id><pub-id pub-id-type="pmcid">PMC4090106</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Mayorov</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Rice</surname><given-names>KC</given-names></string-name></person-group>, <etal>et al</etal><article-title>Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs</article-title>. <source>Vaccine.</source><year>2013</year>; <volume>31</volume>:<fpage>2804</fpage>&#8211;<lpage>2810</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.04.027</pub-id><pub-id pub-id-type="pmid">23624097</pub-id><pub-id pub-id-type="pmcid">PMC4120113</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Antoline</surname><given-names>JF</given-names></string-name></person-group>, <etal>et al</etal><article-title>Synthesis and immunological effects of heroin vaccines</article-title>. <source>Org Biomol Chem.</source><year>2014</year>; <volume>12</volume>:<fpage>7211</fpage>&#8211;<lpage>7232</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1039/c4ob01053a</pub-id><pub-id pub-id-type="pmid">24995943</pub-id><pub-id pub-id-type="pmcid">PMC4146676</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hwang</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Wenthur</surname><given-names>CJ</given-names></string-name></person-group>, <etal>et al</etal><article-title>Enhancing efficacy and stability of an antiheroin vaccine: examination of antinociception, opioid binding profile, and lethality</article-title>. <source>Mol Pharm.</source><year>2018</year>; <volume>15</volume>:<fpage>1062</fpage>&#8211;<lpage>1072</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00933</pub-id><pub-id pub-id-type="pmid">29420901</pub-id><pub-id pub-id-type="pmcid">PMC5912936</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Schlosburg</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Banks</surname><given-names>ML</given-names></string-name></person-group>, <etal>et al</etal><article-title>Development of a clinically viable heroin vaccine</article-title>. <source>J Am Chem Soc.</source><year>2017</year>; <volume>139</volume>:<fpage>8601</fpage>&#8211;<lpage>8611</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/jacs.7b03334</pub-id><pub-id pub-id-type="pmid">28574716</pub-id><pub-id pub-id-type="pmcid">PMC5612493</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gutman</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Irvin</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>JB</given-names></string-name></person-group>, <etal>et al</etal><article-title>Synthesis and immunological effects of C14-linked 4, 5-epoxymorphinan analogues as novel heroin vaccine haptens</article-title>. <source>RSC Chem Biol.</source><year>2021</year>; <volume>2</volume>:<fpage>835</fpage>&#8211;<lpage>842</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1039/d1cb00029b</pub-id><pub-id pub-id-type="pmid">34179783</pub-id><pub-id pub-id-type="pmcid">PMC8190897</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sulima</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>JB</given-names></string-name></person-group>, <etal>et al</etal><article-title>Design, synthesis, and in vivo evaluation of C1-linked 4, 5-epoxymorphinan haptens for heroin vaccines</article-title>. <source>Molecules.</source><year>2022</year>; <volume>27</volume>:<fpage>1553</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.3390/molecules27051553</pub-id><pub-id pub-id-type="pmid">35268659</pub-id><pub-id pub-id-type="pmcid">PMC8911913</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M&#233;ndez</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Matus-Ortega</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Miramontes</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Salazar-Ju&#225;rez</surname><given-names>A.</given-names></string-name></person-group><article-title>Effect of the morphine/heroin vaccine on opioid and non-opioid drug-induced antinociception in mice</article-title>. <source>Eur J Pharmacol.</source><year>2021</year>; <volume>891</volume>:<fpage>173718</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173718</pub-id><pub-id pub-id-type="pmid">33171151</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Janda</surname><given-names>KD.</given-names></string-name></person-group><article-title>Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance</article-title>. <source>J Med Chem.</source><year>2012</year>; <volume>55</volume>:<fpage>10776</fpage>&#8211;<lpage>10780</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/jm301262z</pub-id><pub-id pub-id-type="pmid">23134263</pub-id><pub-id pub-id-type="pmcid">PMC3527012</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Torres</surname><given-names>OB</given-names></string-name>, <string-name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal><article-title>Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant</article-title>. <source>NPJ Vaccines.</source><year>2017</year>; <volume>2</volume>:<fpage>13</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41541-017-0013-9</pub-id><pub-id pub-id-type="pmid">29263870</pub-id><pub-id pub-id-type="pmcid">PMC5604742</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farhangi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Akbarzadeh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mehrabi</surname><given-names>MR</given-names></string-name></person-group>, <etal>et al</etal><article-title>Immunotherapy of 436 morphine addicts by therapeutic morphine vaccine in Kerman Province (I.R. Iran)</article-title>. <source>J Vaccines Vaccin.</source><year>2012</year>; <volume>3</volume>:<fpage>1</fpage>&#8211;<lpage>6</lpage>.</mixed-citation></ref><ref id="CIT0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akbarzadeh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Norouzian</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Farhangi</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal><article-title>Immunotherapy of 347 volunteer outpatient morphine addicts by human therapeutic morphine vaccine in Kermanshah province of Iran</article-title>. <source>J Pharmacol Toxicol.</source><year>2009</year>; <volume>4</volume>:<fpage>30</fpage>&#8211;<lpage>35</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.3923/jpt.2009.30.35</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akbarzadeh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Norouzian</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Farhangi</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal><article-title>Study of human therapeutic morphine vaccine: safety and immunogenicity</article-title>. <source>Asian J Biochem.</source><year>2007</year>; <volume>2</volume>:<fpage>58</fpage>&#8211;<lpage>65</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.3923/ajb.2007.58.65</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sakaguchi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nakayama</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Inouye</surname><given-names>S.</given-names></string-name></person-group><article-title>Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines</article-title>. <source>J Allergy Clin Immunol.</source><year>1996</year>; <volume>98</volume>:<fpage>1058</fpage>&#8211;<lpage>1061</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/s0091-6749(96)80191-6</pub-id><pub-id pub-id-type="pmid">8977505</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loughney</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Lancaster</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rustandi</surname><given-names>RR.</given-names></string-name></person-group><article-title>Residual bovine serum albumin (BSA) quantitation in vaccines using automated Capillary Western technology</article-title>. <source>Anal Biochem.</source><year>2014</year>; <volume>461</volume>:<fpage>49</fpage>&#8211;<lpage>56</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.ab.2014.05.004</pub-id><pub-id pub-id-type="pmid">24841366</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Silva</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dasanayake</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wickramasinhe</surname><given-names>G</given-names></string-name></person-group>, <etal>et al</etal><article-title>Sensitization to bovine serum albumin as a possible cause of allergic reactions to vaccines</article-title>. <source>Vaccine.</source><year>2017</year>; <volume>35</volume>:<fpage>1494</fpage>&#8211;<lpage>1500</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.009</pub-id><pub-id pub-id-type="pmid">28216185</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marie</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Noble</surname><given-names>F.</given-names></string-name></person-group><article-title>Oxycodone, an opioid like the others</article-title>? <source>Front Psychiatry.</source><year>2023</year>; <volume>14</volume>:<fpage>1229439</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.3389/fpsyt.2023.1229439</pub-id><pub-id pub-id-type="pmid">38152360</pub-id><pub-id pub-id-type="pmcid">PMC10751306</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kibaly</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Alderete</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>SH</given-names></string-name></person-group>, <etal>et al</etal><article-title>Oxycodone in the opioid epidemic: high &#8220;liking,&#8221;&#8216;wanting&#8217;, and abuse liability</article-title>. <source>Cell Mol Neurobiol.</source><year>2021</year>; <volume>41</volume>:<fpage>899</fpage>&#8211;<lpage>926</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1007/s10571-020-01013-y</pub-id><pub-id pub-id-type="pmid">33245509</pub-id><pub-id pub-id-type="pmcid">PMC8155122</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hall</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hickman</surname><given-names>M.</given-names></string-name></person-group><article-title>Generational trends in US opioid-overdose deaths</article-title>. <source>Nat Med.</source><year>2020</year>; <volume>26</volume>:<fpage>651</fpage>&#8211;<lpage>652</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41591-020-0875-7</pub-id><pub-id pub-id-type="pmid">32367061</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cicero</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Surratt</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Kurtz</surname><given-names>SP.</given-names></string-name></person-group><article-title>The changing face of heroin use in the United States: a retrospective analysis of the past 50 years</article-title>. <source>JAMA Psychiatry.</source><year>2014</year>; <volume>71</volume>:<fpage>821</fpage>&#8211;<lpage>826</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.366</pub-id><pub-id pub-id-type="pmid">24871348</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kinnunen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Piirainen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kokki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lammi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kokki</surname><given-names>M.</given-names></string-name></person-group><article-title>Updated clinical pharmacokinetics and pharmacodynamics of oxycodone</article-title>. <source>Clin Pharmacokinet.</source><year>2019</year>; <volume>58</volume>:<fpage>705</fpage>&#8211;<lpage>725</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1007/s40262-018-00731-3</pub-id><pub-id pub-id-type="pmid">30652261</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pentel</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Potter</surname><given-names>DN</given-names></string-name></person-group>, <etal>et al</etal><article-title>Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats</article-title>. <source>PLoS One.</source><year>2014</year>; <volume>9</volume>:<fpage>e101807</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1371/journal.pone.0101807</pub-id><pub-id pub-id-type="pmid">25025380</pub-id><pub-id pub-id-type="pmcid">PMC4099132</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nguyen</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Grant</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Janda</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Taffe</surname><given-names>MA.</given-names></string-name></person-group><article-title>Prophylactic vaccination protects against the development of oxycodone self-administration</article-title>. <source>Neuropharmacology.</source><year>2018</year>; <volume>138</volume>:<fpage>292</fpage>&#8211;<lpage>303</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.06.026</pub-id><pub-id pub-id-type="pmid">29936242</pub-id><pub-id pub-id-type="pmcid">PMC6800241</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raleigh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Baruffaldi</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder</article-title>. <source>Neuropharmacology.</source><year>2021</year>; <volume>195</volume>:<fpage>108653</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.neuropharm.2021.108653</pub-id><pub-id pub-id-type="pmid">34126123</pub-id><pub-id pub-id-type="pmcid">PMC8410661</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Le Naour</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Harmon</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal><article-title>An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia</article-title>. <source>J Pharmacol Exp Ther.</source><year>2012</year>; <volume>341</volume>:<fpage>225</fpage>&#8211;<lpage>232</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1124/jpet.111.189506</pub-id><pub-id pub-id-type="pmid">22262924</pub-id><pub-id pub-id-type="pmcid">PMC3310692</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Le Naour</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tucker</surname><given-names>AM</given-names></string-name></person-group>, <etal>et al</etal><article-title>Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens</article-title>. <source>J Med Chem.</source><year>2013</year>; <volume>56</volume>:<fpage>915</fpage>&#8211;<lpage>923</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/jm3013745</pub-id><pub-id pub-id-type="pmid">23249238</pub-id><pub-id pub-id-type="pmcid">PMC3791856</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Laudenbach</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baruffaldi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal><article-title>Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose</article-title>. <source>Sci Rep.</source><year>2018</year>; <volume>8</volume>:<fpage>5508</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41598-018-23777-6</pub-id><pub-id pub-id-type="pmid">29615715</pub-id><pub-id pub-id-type="pmcid">PMC5882912</pub-id></mixed-citation></ref><ref id="CIT0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Taylor</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Laudenbach</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tucker</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jenkins</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pravetoni</surname><given-names>M.</given-names></string-name></person-group><article-title>Hapten-specific naive B cells are biomarkers of vaccine efficacy against drugs of abuse</article-title>. <source>J Immunol Methods.</source><year>2014</year>; <volume>405</volume>:<fpage>74</fpage>&#8211;<lpage>86</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.jim.2014.01.010</pub-id><pub-id pub-id-type="pmid">24462800</pub-id><pub-id pub-id-type="pmcid">PMC4018303</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robinson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Baehr</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schmiel</surname><given-names>SE</given-names></string-name></person-group>, <etal>et al</etal><article-title>Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders</article-title>. <source>Hum Vaccin Immunother.</source><year>2019</year>; <volume>15</volume>:<fpage>909</fpage>&#8211;<lpage>917</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1080/21645515.2018.1558697</pub-id><pub-id pub-id-type="pmid">30625019</pub-id><pub-id pub-id-type="pmcid">PMC6605845</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baruffaldi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kelcher</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Laudenbach</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal><article-title>Preclinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins</article-title>. <source>Mol Pharm.</source><year>2018</year>; <volume>15</volume>:<fpage>4947</fpage>&#8211;<lpage>4962</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00592</pub-id><pub-id pub-id-type="pmid">30240216</pub-id><pub-id pub-id-type="pmcid">PMC6361123</pub-id></mixed-citation></ref><ref id="CIT0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raleigh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Laudenbach</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal><article-title>Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse</article-title>. <source>PLoS One.</source><year>2017</year>; <volume>12</volume>:<fpage>e0184876</fpage>.<pub-id pub-id-type="pmid">29194445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0184876</pub-id><pub-id pub-id-type="pmcid">PMC5711015</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crouse</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Baehr</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hicks</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pravetoni</surname><given-names>M.</given-names></string-name></person-group><article-title>IL-4 predicts the efficacy of a candidate antioxycodone vaccine and alters vaccine-specific antibody-secreting cell proliferation in mice</article-title>. <source>J Immunol.</source><year>2023</year>; <volume>210</volume>:<fpage>1272</fpage>&#8211;<lpage>1280</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.4049/jimmunol.2200605</pub-id><pub-id pub-id-type="pmid">36939374</pub-id><pub-id pub-id-type="pmcid">PMC11321710</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Laudenbach</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baruffaldi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Vervacke</surname><given-names>JS</given-names></string-name></person-group>, <etal>et al</etal><article-title>The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse</article-title>. <source>J Immunol.</source><year>2015</year>; <volume>194</volume>:<fpage>5926</fpage>&#8211;<lpage>5936</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.4049/jimmunol.1500385</pub-id><pub-id pub-id-type="pmid">25972483</pub-id><pub-id pub-id-type="pmcid">PMC4458396</pub-id></mixed-citation></ref><ref id="CIT0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hamid</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Marker</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Raleigh</surname><given-names>MD</given-names></string-name></person-group>, <etal>et al</etal><article-title>Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder</article-title>. <source>Vaccine.</source><year>2022</year>; <volume>40</volume>:<fpage>3244</fpage>&#8211;<lpage>3252</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2022.03.053</pub-id><pub-id pub-id-type="pmid">35469698</pub-id><pub-id pub-id-type="pmcid">PMC9186020</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crouse</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Huseby Kelcher</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal><article-title>Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders</article-title>. <source>NPJ Vaccines.</source><year>2020</year>; <volume>5</volume>:<fpage>99</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41541-020-00247-7</pub-id><pub-id pub-id-type="pmid">33101712</pub-id><pub-id pub-id-type="pmcid">PMC7578047</pub-id></mixed-citation></ref><ref id="CIT0087"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crouse</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal><article-title>Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats</article-title>. <source>Hum Vaccin Immunother.</source><year>2021</year>; <volume>17</volume>:<fpage>4383</fpage>&#8211;<lpage>4392</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1080/21645515.2021.1954442</pub-id><pub-id pub-id-type="pmid">34411500</pub-id><pub-id pub-id-type="pmcid">PMC8828096</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gradinati</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Baruffaldi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Abbaraju</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity</article-title>. <source>Vaccine.</source><year>2020</year>; <volume>38</volume>:<fpage>4704</fpage>&#8211;<lpage>4712</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2020.05.027</pub-id><pub-id pub-id-type="pmid">32439214</pub-id><pub-id pub-id-type="pmcid">PMC8268746</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kimishima</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wenthur</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Janda</surname><given-names>KD.</given-names></string-name></person-group><article-title>An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life</article-title>. <source>ACS Chem Biol.</source><year>2017</year>; <volume>12</volume>:<fpage>36</fpage>&#8211;<lpage>40</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acschembio.6b00977</pub-id><pub-id pub-id-type="pmid">28103678</pub-id><pub-id pub-id-type="pmcid">PMC6434689</pub-id></mixed-citation></ref><ref id="CIT0090"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raleigh</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Laudenbach</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baruffaldi</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>Opioid dose-and route-dependent efficacy of oxycodone and heroin vaccines in rats</article-title>. <source>J Pharmacol Exp Ther.</source><year>2018</year>; <volume>365</volume>:<fpage>346</fpage>&#8211;<lpage>353</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1124/jpet.117.247049</pub-id><pub-id pub-id-type="pmid">29535156</pub-id><pub-id pub-id-type="pmcid">PMC5884377</pub-id></mixed-citation></ref><ref id="CIT0091"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jalal</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Burke</surname><given-names>DS.</given-names></string-name></person-group><article-title>Carfentanil and the rise and fall of overdose deaths in the United States</article-title>. <source>Addiction.</source><year>2021</year>; <volume>116</volume>:<fpage>1593</fpage>&#8211;<lpage>1599</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1111/add.15260</pub-id><pub-id pub-id-type="pmid">32935381</pub-id><pub-id pub-id-type="pmcid">PMC8019064</pub-id></mixed-citation></ref><ref id="CIT0092"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gladden</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Seth</surname><given-names>P.</given-names></string-name></person-group><article-title>Fentanyl law enforcement submissions and increases in synthetic opioid&#8211;involved overdose deaths&#8212;27 states, 2013&#8211;2014</article-title>. <source>Morb Mortal Wkly Rep.</source><year>2016</year>; <volume>65</volume>:<fpage>837</fpage>&#8211;<lpage>843</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6533a2</pub-id><pub-id pub-id-type="pmid">27560775</pub-id></mixed-citation></ref><ref id="CIT0093"><label>93.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Baumgartner</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Radley</surname><given-names>D.</given-names></string-name></person-group><source>The Drug Overdose Toll in 2020 and Near-Term Actions for Addressing It</source>. <publisher-name>The Commonwealth Fund</publisher-name>; <year>2021</year>.</mixed-citation></ref><ref id="CIT0094"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Armenian</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vo</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Barr-Walker</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lynch</surname><given-names>KL.</given-names></string-name></person-group><article-title>Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review</article-title>. <source>Neuropharmacology.</source><year>2018</year>; <volume>134</volume>:<fpage>121</fpage>&#8211;<lpage>132</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.10.016</pub-id><pub-id pub-id-type="pmid">29042317</pub-id></mixed-citation></ref><ref id="CIT0095"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schmid</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Kennedy</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Ross</surname><given-names>NC</given-names></string-name></person-group>, <etal>et al</etal><article-title>Bias factor and therapeutic window correlate to predict safer opioid analgesics</article-title>. <source>Cell.</source><year>2017</year>; <volume>171</volume>:<fpage>1165</fpage>&#8211;<lpage>1175.e13</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.cell.2017.10.035</pub-id><pub-id pub-id-type="pmid">29149605</pub-id><pub-id pub-id-type="pmcid">PMC5731250</pub-id></mixed-citation></ref><ref id="CIT0096"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miller</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Crouse</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hicks</surname><given-names>L</given-names></string-name></person-group>, <etal>et al</etal><article-title>A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice</article-title>. <source>NPJ Vaccines.</source><year>2023</year>; <volume>8</volume>:<fpage>97</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41541-023-00694-y</pub-id><pub-id pub-id-type="pmid">37429853</pub-id><pub-id pub-id-type="pmcid">PMC10333387</pub-id></mixed-citation></ref><ref id="CIT0097"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Einstein</surname><given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Compton</surname><given-names>WM.</given-names></string-name></person-group><article-title>Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016</article-title>. <source>JAMA.</source><year>2018</year>; <volume>319</volume>:<fpage>1819</fpage>&#8211;<lpage>1821</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1001/jama.2018.2844</pub-id><pub-id pub-id-type="pmid">29715347</pub-id><pub-id pub-id-type="pmcid">PMC6583033</pub-id></mixed-citation></ref><ref id="CIT0098"><label>98.</label><mixed-citation publication-type="journal"><collab>CDC&#8208;NCHS. U.S</collab>. <italic toggle="yes">Overdose Deaths Decrease in 2023, First Time Since 2018.</italic> Accessed <comment>August 8, 2024</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm" ext-link-type="uri">https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm</ext-link></mixed-citation></ref><ref id="CIT0099"><label>99.</label><mixed-citation publication-type="journal"><collab>Administration DE</collab>. DEA laboratory testing reveals that 6 out of 10 fentanyl-laced fake prescription pills now contain a potentially lethal dose of fentanyl. <year>2024</year>. Accessed <comment>November 26, 2024</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dea.gov/alert/dea-laboratory-testing-reveals-6-out-10-fentanyl-laced-fake-prescription-pills-now-contain" ext-link-type="uri">https://www.dea.gov/alert/dea-laboratory-testing-reveals-6-out-10-fentanyl-laced-fake-prescription-pills-now-contain</ext-link></mixed-citation></ref><ref id="CIT0100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suzuki</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>El-Haddad</surname><given-names>S.</given-names></string-name></person-group><article-title>A review: fentanyl and non-pharmaceutical fentanyls</article-title>. <source>Drug Alcohol Depend.</source><year>2017</year>; <volume>171</volume>:<fpage>107</fpage>&#8211;<lpage>116</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.11.033</pub-id><pub-id pub-id-type="pmid">28068563</pub-id></mixed-citation></ref><ref id="CIT0101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Volkow</surname><given-names>ND.</given-names></string-name></person-group><article-title>The epidemic of fentanyl misuse and overdoses: challenges and strategies</article-title>. <source>World Psychiatry.</source><year>2021</year>; <volume>20</volume>:<fpage>195</fpage>&#8211;<lpage>196</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1002/wps.20846</pub-id><pub-id pub-id-type="pmid">34002497</pub-id><pub-id pub-id-type="pmcid">PMC8129846</pub-id></mixed-citation></ref><ref id="CIT0102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prekupec</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mansky</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Baumann</surname><given-names>M.</given-names></string-name></person-group><article-title>Misuse of novel synthetic opioids: a deadly new trend</article-title>. <source>J Addict Med.</source><year>2017</year>; <volume>11</volume>:<fpage>256</fpage>&#8211;<lpage>265</lpage>.<pub-id pub-id-type="pmid">28590391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000000324</pub-id><pub-id pub-id-type="pmcid">PMC5537029</pub-id></mixed-citation></ref><ref id="CIT0103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tunstall</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Vendruscolo</surname><given-names>LF.</given-names></string-name></person-group><article-title>Utility of fentanyl vaccines: unique challenges posed by preventing opioid overdose and treating opioid use disorder</article-title>. <source>Neuropsychopharmacology.</source><year>2019</year>; <volume>44</volume>:<fpage>1675</fpage>&#8211;<lpage>1676</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41386-019-0418-4</pub-id><pub-id pub-id-type="pmid">31127167</pub-id><pub-id pub-id-type="pmcid">PMC6785139</pub-id></mixed-citation></ref><ref id="CIT0104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Han</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name></person-group>, <etal>et al</etal><article-title>The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies</article-title>. <source>Transl Psychiatry.</source><year>2019</year>; <volume>9</volume>:<fpage>282</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41398-019-0625-0</pub-id><pub-id pub-id-type="pmid">31712552</pub-id><pub-id pub-id-type="pmcid">PMC6848196</pub-id></mixed-citation></ref><ref id="CIT0105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wilson</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kariisa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Seth</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>H</given-names><suffix>IV</suffix></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>NL.</given-names></string-name></person-group><article-title>Drug and opioid-involved overdose deaths&#8212;United States, 2017&#8211;2018</article-title>. <source>Morb Mortal Wkly Rep.</source><year>2020</year>; <volume>69</volume>:<fpage>290</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6911a4</pub-id><pub-id pub-id-type="pmcid">PMC7739981</pub-id><pub-id pub-id-type="pmid">32191688</pub-id></mixed-citation></ref><ref id="CIT0106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Townsend</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Blake</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Faunce</surname><given-names>KE</given-names></string-name></person-group>, <etal>et al</etal><article-title>Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats</article-title>. <source>Neuropsychopharmacology.</source><year>2019</year>; <volume>44</volume>:<fpage>1681</fpage>&#8211;<lpage>1689</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41386-019-0385-9</pub-id><pub-id pub-id-type="pmid">31043682</pub-id><pub-id pub-id-type="pmcid">PMC6784909</pub-id></mixed-citation></ref><ref id="CIT0107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tenney</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Blake</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name></person-group>, <etal>et al</etal><article-title>Vaccine blunts fentanyl potency in male rhesus monkeys</article-title>. <source>Neuropharmacology.</source><year>2019</year>; <volume>158</volume>:<fpage>107730</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.107730</pub-id><pub-id pub-id-type="pmid">31369740</pub-id><pub-id pub-id-type="pmcid">PMC6745253</pub-id></mixed-citation></ref><ref id="CIT0108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haile</surname><given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Sanchez</surname><given-names>SA</given-names></string-name></person-group>, <etal>et al</etal><article-title>An immunconjugate vaccine alters distribution and reduces the antinociceptive, behavioral and physiological effects of fentanyl in male and female rats</article-title>. <source>Pharmaceutics.</source><year>2022</year>; <volume>14</volume>:<fpage>2290</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.3390/pharmaceutics14112290</pub-id><pub-id pub-id-type="pmid">36365109</pub-id><pub-id pub-id-type="pmcid">PMC9694531</pub-id></mixed-citation></ref><ref id="CIT0109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stone</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Scheuermann</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Haile</surname><given-names>CN</given-names></string-name></person-group>, <etal>et al</etal><article-title>Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge</article-title>. <source>NPJ Vaccines.</source><year>2021</year>; <volume>6</volume>:<fpage>69</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41541-021-00329-0</pub-id><pub-id pub-id-type="pmid">33986280</pub-id><pub-id pub-id-type="pmcid">PMC8119695</pub-id></mixed-citation></ref><ref id="CIT0110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barrientos</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Bow</surname><given-names>EW</given-names></string-name>, <string-name name-style="western"><surname>Whalen</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal><article-title>Novel vaccine that blunts fentanyl effects and sequesters ultrapotent fentanyl analogues</article-title>. <source>Mol Pharm.</source><year>2020</year>; <volume>17</volume>:<fpage>3447</fpage>&#8211;<lpage>3460</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00497</pub-id><pub-id pub-id-type="pmid">32787282</pub-id><pub-id pub-id-type="pmcid">PMC7482402</pub-id></mixed-citation></ref><ref id="CIT0111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal><article-title>A fentanyl vaccine constructed upon opsonizing antibodies specific for the Gal&#945;1&#8211;3Gal epitope</article-title>. <source>Chem Commun (Camb).</source><year>2020</year>; <volume>56</volume>:<fpage>6551</fpage>&#8211;<lpage>6554</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1039/d0cc02107e</pub-id><pub-id pub-id-type="pmid">32396160</pub-id><pub-id pub-id-type="pmcid">PMC7398699</pub-id></mixed-citation></ref><ref id="CIT0112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raleigh</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Baruffaldi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>SJ</given-names></string-name></person-group>, <etal>et al</etal><article-title>A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats</article-title>. <source>J Pharmacol Exp Ther.</source><year>2019</year>; <volume>368</volume>:<fpage>282</fpage>&#8211;<lpage>291</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1124/jpet.118.253674</pub-id><pub-id pub-id-type="pmid">30409833</pub-id><pub-id pub-id-type="pmcid">PMC6346379</pub-id></mixed-citation></ref><ref id="CIT0113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robinson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gradinati</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Hamid</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity</article-title>. <source>J Med Chem.</source><year>2020</year>; <volume>63</volume>:<fpage>14647</fpage>&#8211;<lpage>14667</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01042</pub-id><pub-id pub-id-type="pmid">33215913</pub-id><pub-id pub-id-type="pmcid">PMC8193686</pub-id></mixed-citation></ref><ref id="CIT0114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eubanks</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Blake</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Natori</surname><given-names>Y</given-names></string-name></person-group>, <etal>et al</etal><article-title>A highly efficacious carfentanil vaccine that blunts opioid-induced antinociception and respiratory depression</article-title>. <source>ACS Chem Biol.</source><year>2021</year>; <volume>16</volume>:<fpage>277</fpage>&#8211;<lpage>282</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acschembio.1c00026</pub-id><pub-id pub-id-type="pmid">33533592</pub-id><pub-id pub-id-type="pmcid">PMC8260150</pub-id></mixed-citation></ref><ref id="CIT0115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baehr</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kassick</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal><article-title>Preclinical efficacy and selectivity of vaccines targeting fentanyl, alfentanil, sufentanil, and acetylfentanyl in rats</article-title>. <source>ACS Omega.</source><year>2022</year>; <volume>7</volume>:<fpage>16584</fpage>&#8211;<lpage>16592</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acsomega.2c00820</pub-id><pub-id pub-id-type="pmid">35601290</pub-id><pub-id pub-id-type="pmcid">PMC9118421</pub-id></mixed-citation></ref><ref id="CIT0116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Kimishima</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schlosburg</surname><given-names>JE</given-names></string-name></person-group>, <etal>et al</etal><article-title>Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs</article-title>. <source>Angew Chem Int Ed Engl.</source><year>2016</year>; <volume>55</volume>:<fpage>3772</fpage>&#8211;<lpage>3775</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1002/anie.201511654</pub-id><pub-id pub-id-type="pmid">26879590</pub-id><pub-id pub-id-type="pmcid">PMC4860013</pub-id></mixed-citation></ref><ref id="CIT0117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Townsend</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Jacob</surname><given-names>NT</given-names></string-name></person-group>, <etal>et al</etal><article-title>A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys</article-title>. <source>Drug Alcohol Depend.</source><year>2021</year>; <volume>218</volume>:<fpage>108348</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.108348</pub-id><pub-id pub-id-type="pmid">33268227</pub-id><pub-id pub-id-type="pmcid">PMC8224470</pub-id></mixed-citation></ref><ref id="CIT0118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Park</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name></person-group><article-title>Development of a vaccine against the synthetic opioid U-47700</article-title>. <source>Front Pharmacol.</source><year>2023</year>; <volume>14</volume>:<fpage>1219985</fpage>.<pub-id pub-id-type="pmid">37492086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2023.1219985</pub-id><pub-id pub-id-type="pmcid">PMC10363602</pub-id></mixed-citation></ref><ref id="CIT0119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zawilska</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Adamowicz</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kurpeta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wojcieszak</surname><given-names>J.</given-names></string-name></person-group><article-title>Non-fentanyl new synthetic opioids &#8211; an update</article-title>. <source>Forensic Sci Int.</source><year>2023</year>; <volume>349</volume>:<fpage>111775</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.forsciint.2023.111775</pub-id><pub-id pub-id-type="pmid">37423031</pub-id></mixed-citation></ref><ref id="CIT0120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Eubanks</surname><given-names>LM</given-names></string-name></person-group>, <etal>et al</etal><article-title>A Vaccine against benzimidazole-derived new psychoactive substances that are more potent than fentanyl</article-title>. <source>J Med Chem.</source><year>2022</year>; <volume>65</volume>:<fpage>2522</fpage>&#8211;<lpage>2531</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c01967</pub-id><pub-id pub-id-type="pmid">34994550</pub-id></mixed-citation></ref><ref id="CIT0121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ciccarone</surname><given-names>D.</given-names></string-name></person-group><article-title>Fentanyl in the US heroin supply: a rapidly changing risk environment</article-title>. <source>Int J Drug Policy.</source><year>2017</year>; <volume>46</volume>:<fpage>107</fpage>&#8211;<lpage>111</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.drugpo.2017.06.010</pub-id><pub-id pub-id-type="pmid">28735776</pub-id><pub-id pub-id-type="pmcid">PMC5742018</pub-id></mixed-citation></ref><ref id="CIT0122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soc&#237;as</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>E.</given-names></string-name></person-group><article-title>Epidemic of deaths from fentanyl overdose</article-title>. <source>BMJ.</source><year>2017</year>; <volume>358</volume>:<fpage>j4355</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1136/bmj.j4355</pub-id><pub-id pub-id-type="pmid">28963094</pub-id></mixed-citation></ref><ref id="CIT0123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gostin</surname><given-names>LO</given-names></string-name>, <string-name name-style="western"><surname>Hodge</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Noe</surname><given-names>SA.</given-names></string-name></person-group><article-title>Reframing the opioid epidemic as a national emergency</article-title>. <source>JAMA.</source><year>2017</year>; <volume>318</volume>:<fpage>1539</fpage>&#8211;<lpage>1540</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1001/jama.2017.13358</pub-id><pub-id pub-id-type="pmid">28832871</pub-id></mixed-citation></ref><ref id="CIT0124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Solis</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cameron-Burr</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Kiyatkin</surname><given-names>EA.</given-names></string-name></person-group><article-title>Heroin contaminated with fentanyl dramatically enhances brain hypoxia and induces brain hypothermia</article-title>. <source>eNeuro</source>. <year>2017</year>; <volume>4</volume>:<fpage>ENEURO.0323</fpage>&#8211;<lpage>ENEU17.2017</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1523/ENEURO.0323-17.2017</pub-id><pub-id pub-id-type="pmid">29085909</pub-id><pub-id pub-id-type="pmcid">PMC5661359</pub-id></mixed-citation></ref><ref id="CIT0125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Martinez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chao</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal><article-title>The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis</article-title>. <source>Expert Opin Investig Drugs.</source><year>2023</year>; <volume>32</volume>:<fpage>181</fpage>&#8211;<lpage>185</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1080/13543784.2023.2187286</pub-id><pub-id pub-id-type="pmcid">PMC10065938</pub-id><pub-id pub-id-type="pmid">36863002</pub-id></mixed-citation></ref><ref id="CIT0126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hwang</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Natori</surname><given-names>Y</given-names></string-name></person-group>, <etal>et al</etal><article-title>Improved admixture vaccine of fentanyl and heroin hapten immunoconjugates: antinociceptive evaluation of fentanyl-contaminated heroin</article-title>. <source>ACS Omega.</source><year>2018</year>; <volume>3</volume>:<fpage>11537</fpage>&#8211;<lpage>11543</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acsomega.8b01478</pub-id><pub-id pub-id-type="pmid">30288464</pub-id><pub-id pub-id-type="pmcid">PMC6166218</pub-id></mixed-citation></ref><ref id="CIT0127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hwang</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Natori</surname><given-names>Y</given-names></string-name></person-group>, <etal>et al</etal><article-title>Efficacious vaccine against heroin contaminated with fentanyl</article-title>. <source>ACS Chem Neurosci.</source><year>2018</year>; <volume>9</volume>:<fpage>1269</fpage>&#8211;<lpage>1275</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acschemneuro.8b00079</pub-id><pub-id pub-id-type="pmid">29558798</pub-id><pub-id pub-id-type="pmcid">PMC6013375</pub-id></mixed-citation></ref><ref id="CIT0128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barrientos</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Whalen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Torres</surname><given-names>OB</given-names></string-name></person-group>, <etal>et al</etal><article-title>Bivalent conjugate vaccine induces dual immunogenic response that attenuates heroin and fentanyl effects in mice</article-title>. <source>Bioconjug Chem.</source><year>2021</year>; <volume>32</volume>:<fpage>2295</fpage>&#8211;<lpage>2306</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acs.bioconjchem.1c00179</pub-id><pub-id pub-id-type="pmid">34076427</pub-id><pub-id pub-id-type="pmcid">PMC8603354</pub-id></mixed-citation></ref><ref id="CIT0129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blake</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal><article-title>Developing translational vaccines against heroin and fentanyl through investigation of adjuvants and stability</article-title>. <source>Mol Pharm.</source><year>2020</year>; <volume>18</volume>:<fpage>228</fpage>&#8211;<lpage>235</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00837</pub-id><pub-id pub-id-type="pmid">33301675</pub-id><pub-id pub-id-type="pmcid">PMC9946458</pub-id></mixed-citation></ref><ref id="CIT0130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baruffaldi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Raleigh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>Formulation and characterization of conjugate vaccines to reduce opioid use disorders suitable for pharmaceutical manufacturing and clinical evaluation</article-title>. <source>Mol Pharm.</source><year>2019</year>; <volume>16</volume>:<fpage>2364</fpage>&#8211;<lpage>2375</lpage>.<pub-id pub-id-type="pmid">31018096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.8b01296</pub-id><pub-id pub-id-type="pmcid">PMC6598681</pub-id></mixed-citation></ref><ref id="CIT0131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crouse</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Gradinati</surname><given-names>V</given-names></string-name></person-group>, <etal>et al</etal><article-title>Efficacy and selectivity of monovalent and bivalent vaccination strategies to protect against exposure to carfentanil, fentanyl, and their mixtures in rats</article-title>. <source>ACS Pharmacol Transl Sci.</source><year>2022</year>; <volume>5</volume>:<fpage>331</fpage>&#8211;<lpage>343</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acsptsci.1c00260</pub-id><pub-id pub-id-type="pmid">35592436</pub-id><pub-id pub-id-type="pmcid">PMC9112413</pub-id></mixed-citation></ref><ref id="CIT0132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Townsend</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Faunce</surname><given-names>KE</given-names></string-name></person-group>, <etal>et al</etal><article-title>Evaluation of a dual fentanyl/heroin vaccine on the antinociceptive and reinforcing effects of a fentanyl/heroin mixture in male and female rats</article-title>. <source>ACS Chem Neurosci.</source><year>2020</year>; <volume>11</volume>:<fpage>1300</fpage>&#8211;<lpage>1310</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1021/acschemneuro.0c00064</pub-id><pub-id pub-id-type="pmid">32271538</pub-id><pub-id pub-id-type="pmcid">PMC7531604</pub-id></mixed-citation></ref><ref id="CIT0133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Raleigh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Le Naour</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal><article-title>Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats</article-title>. <source>Vaccine.</source><year>2012</year>; <volume>30</volume>:<fpage>4617</fpage>&#8211;<lpage>4624</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.101</pub-id><pub-id pub-id-type="pmid">22583811</pub-id><pub-id pub-id-type="pmcid">PMC3372705</pub-id></mixed-citation></ref><ref id="CIT0134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Park</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Eubanks</surname><given-names>LM</given-names></string-name></person-group>, <etal>et al</etal><article-title>Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin</article-title>. <source>Bioorg Med Chem.</source><year>2021</year>; <volume>41</volume>:<fpage>116225</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.bmc.2021.116225</pub-id><pub-id pub-id-type="pmid">34034147</pub-id></mixed-citation></ref><ref id="CIT0135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Palis</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xavier</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dobrer</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>Concurrent use of opioids and stimulants and risk of fatal overdose: a cohort study</article-title>. <source>BMC Public Health.</source><year>2022</year>; <volume>22</volume>:<fpage>2084</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1186/s12889-022-14506-w</pub-id><pub-id pub-id-type="pmid">36380298</pub-id><pub-id pub-id-type="pmcid">PMC9664696</pub-id></mixed-citation></ref><ref id="CIT0136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wartenweiler</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wenthur</surname><given-names>C.</given-names></string-name></person-group><article-title>Pharmacy stakeholder reports on ethical and logistical considerations in anti-opioid vaccine development</article-title>. <source>BMC Med Ethics.</source><year>2021</year>; <volume>22</volume>:<fpage>1</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">33766021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12910-021-00599-2</pub-id><pub-id pub-id-type="pmcid">PMC7992836</pub-id></mixed-citation></ref><ref id="CIT0137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Young</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Sisti</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Rimon-Greenspan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Caplan</surname><given-names>AL.</given-names></string-name></person-group><article-title>Immune to addiction: the ethical dimensions of vaccines against substance abuse</article-title>. <source>Nat Immunol.</source><year>2012</year>; <volume>13</volume>:<fpage>521</fpage>&#8211;<lpage>524</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/ni.2321</pub-id><pub-id pub-id-type="pmid">22610239</pub-id></mixed-citation></ref><ref id="CIT0138"><label>138.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Carter</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Capps</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>WD.</given-names></string-name> Chapter 5 -</person-group><source>Emerging Neurobiological Treatments of Addiction: Ethical and Public Policy Considerations.</source> In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Carter</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Illes</surname><given-names>J</given-names></string-name></person-group>, eds. <publisher-name>Addict Neuroethics. Academic Press</publisher-name>; <year>2012</year>:<fpage>95</fpage>&#8211;<lpage>113</lpage>.</mixed-citation></ref><ref id="CIT0139"><label>139.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Montoya</surname><given-names>ID.</given-names></string-name></person-group><article-title>Ethical considerations of biologics to treat substance use disorders. In:</article-title><person-group person-group-type="editor"><string-name name-style="western"><surname>Montoya</surname><given-names>ID</given-names></string-name></person-group>, ed. <source>Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes</source>. <publisher-name>Springer International Publishing</publisher-name>,&#160;<year>2016</year>:<fpage>425</fpage>&#8211;<lpage>437</lpage>.</mixed-citation></ref><ref id="CIT0140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weitzman</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Alegria</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Caplan</surname><given-names>A</given-names></string-name></person-group><article-title>Social complexity of a fentanyl vaccine to prevent opioid overdose conference proceedings: Radcliffe Institute for Advanced Study conference proceedings</article-title>. <source>Vaccine.</source><year>2024</year>; <volume>44</volume>:<fpage>126324</fpage>.<pub-id pub-id-type="pmid">39317618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2024.126324</pub-id></mixed-citation></ref><ref id="CIT0141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Orson</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Kosten</surname><given-names>TR.</given-names></string-name></person-group><article-title>Vaccines against drug abuse</article-title>. <source>Clin Pharmacol Ther.</source><year>2012</year>; <volume>91</volume>:<fpage>60</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">22130115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2011.281</pub-id><pub-id pub-id-type="pmcid">PMC3345810</pub-id></mixed-citation></ref><ref id="CIT0142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Essali</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Goldsmith</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Carbone</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>BJ.</given-names></string-name></person-group><article-title>Psychosis as an adverse effect of monoclonal antibody immunotherapy</article-title>. <source>Brain Behav Immun.</source><year>2019</year>; <volume>81</volume>:<fpage>646</fpage>&#8211;<lpage>649</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1016/j.bbi.2019.06.002</pub-id><pub-id pub-id-type="pmid">31170448</pub-id><pub-id pub-id-type="pmcid">PMC8210540</pub-id></mixed-citation></ref><ref id="CIT0143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Evrensel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>&#220;nsalver</surname><given-names>B&#214;</given-names></string-name>, <string-name name-style="western"><surname>Ceylan</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Tarhan</surname><given-names>N.</given-names></string-name></person-group><article-title>Vaccination and immunotherapy for major depression</article-title>. <source><italic toggle="yes">Adv Exp Med Biol.</italic></source><year>2021</year>; <volume>1305</volume>:<fpage>503</fpage>&#8211;<lpage>513</lpage>. https://doi.org/<pub-id pub-id-type="doi">10.1007/978-981-33-6044-0_25</pub-id><pub-id pub-id-type="pmid">33834415</pub-id></mixed-citation></ref><ref id="CIT0144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Denzel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Runge</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Feige</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal><article-title>Autoantibodies in patients with obsessive-compulsive disorder: a systematic review</article-title>. <source>Transl Psychiatry.</source><year>2023</year>; <volume>13</volume>:<fpage>241</fpage>. https://doi.org/<pub-id pub-id-type="doi">10.1038/s41398-023-02545-9</pub-id><pub-id pub-id-type="pmid">37400462</pub-id><pub-id pub-id-type="pmcid">PMC10318087</pub-id></mixed-citation></ref><ref id="CIT0145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Agdere</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Topaloglu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Erata</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Karacetin</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Yapici</surname><given-names>Z.</given-names></string-name></person-group><article-title>Immunotherapy in autism spectrum disorder; a case series</article-title>. <source>Eur Psychiatry.</source><year>2023</year>; <volume>66</volume>:<fpage>S582</fpage>&#8211;<lpage>S582</lpage>.</mixed-citation></ref><ref id="CIT0146"><label>146.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma&#8217;arfi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hasan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Khanam</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Husain</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>MHR</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>MY.</given-names></string-name></person-group><article-title>Immunotherapy: an approach to treat Alzheimer&#8217;s disease and autism spectrum disorder</article-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><prefix>Md</prefix><surname>Ashraf</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Alexiou</surname><given-names>A</given-names></string-name></person-group>, eds. <source>Autism Spectrum Disorder and Alzheimer&#8217;s Disease: Advances in Research</source>. <publisher-name>Springer Nature Singapore</publisher-name>; <year>2022</year>:<fpage>191</fpage>&#8211;<lpage>214</lpage>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>